<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Anti-Cancer Drugs & Immunosuppressants - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  background: url("assets/background.jpg") center center / cover no-repeat fixed;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
}

body::before {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* Responsive utilities */
@media (max-width: 768px) {
  .glass-card {
    border-radius: 16px;
  }
  
  .glass {
    border-radius: 12px;
  }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">46</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="flex container mx-auto px-6 gap-8">
        <!-- Question Navigation Sidebar -->
        <div class="w-80 glass p-6 h-fit sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="flex-1 max-w-4xl">
            <div class="glass-card p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <!-- Explanation Video -->
                    <div id="solutionVideo" class="hidden">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

    <script>
        let questionsData = [
  {
    "id": 10904,
    "choices": [
      {
        "id": 43582,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute lymphoblastic leukemia (ALL) </span></span></span></p>"
      },
      {
        "id": 43583,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute Myeloblastic Leukemia (AML)</span></span></span></p>"
      },
      {
        "id": 43584,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic lymphocyctic leukemia (CLL)</span></span></span></p>"
      },
      {
        "id": 43585,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic Myelocytic Leukemia (CML)</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 7-year-old child is started on chemotherapy. One of the medications used in the treatment is L-asparaginase. This drug works by depleting asparagine, an amino acid that is required for the growth and survival of leukemia cells. Which of the following cancers is L-asparaginase commonly used to treat?</span></span></span></p>",
    "unique_key": "Q8118107",
    "question_audio": null,
    "question_video": null,
    "map_id": 36455,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Acute lymphoblastic leukemia (ALL)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>L-asparaginase </strong>is an enzyme that is <strong>used in the treatment of acute lymphoblastic leukemia (ALL)</strong>. <strong>ALL</strong> is a cancer of the <strong>blood and bone marrow</strong> that affects <strong>white blood cells.</strong> The drug works by<strong> depleting the level of the amino acid</strong> <strong>asparagine</strong>, which is required for the<strong> growth and survival of leukemia cells.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Normal cells</strong> can <strong>synthesize asparagine</strong>, but <strong>leukemia cells</strong> are <strong>unable</strong> to do so and rely on an <strong>external source </strong>of <strong>asparagine for survival</strong>. <strong>L-asparaginase</strong> works by <strong>breaking down asparagine</strong> in the blood, thus <strong>depriving</strong> the <strong>leukemia</strong> <strong>cells of the amino acid</strong> that they need to<strong> survive.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>L-asparaginase </strong>is typically used in <strong>combination with other chemotherapeutic agents</strong> in the treatment of<strong> ALL</strong>. While it is generally <strong>well tolerated,</strong> it can cause a<strong> few side effects,</strong> including <strong>hypersensitivity reactions</strong>, <strong>coagulation disorders</strong>, and <strong>liver dysfunction. </strong>In addition,<strong> L-asparaginase</strong> can also deplete other <strong>essential amino acids</strong>, which can <strong>lead </strong>to a range of <strong>adverse effects,</strong> including <strong>pancreatitis, hyperglycaemia, and neurological complications.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute Myeloblastic Leukemia (AML):</span></strong><span style=\"font-size:12.0pt\"> AML is another <strong>type of leukemia</strong> but primarily affects <strong>different lineages of cells</strong> within the<strong> bone marrow</strong>.<strong> L-asparaginase</strong> is <strong>not</strong> typically<strong> used</strong> in the treatment of<strong> AML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chronic lymphocytic leukemia (CLL):</span></strong><span style=\"font-size:12.0pt\"> CLL <strong>progresses</strong> <strong>more slowly than ALL </strong>and generally affects<strong> older adults.</strong> It is <strong>not</strong> treated with<strong> L-asparaginase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Chronic Myelocytic Leukemia (CML):</span></strong><span style=\"font-size:12.0pt\"> CML is a<strong> chronic form of leukemia </strong>affecting primarily <strong>adults</strong>.<strong> L-asparaginase</strong> is <strong>not</strong> effective<strong> against CML cells</strong> as they<strong> do not</strong> rely on<strong> external sources of asparagine</strong> like<strong> ALL cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>L-asparaginase</strong> is particularly significant in the <strong>treatment of acute lymphoblastic leukemia (ALL) </strong>due to its unique mechanism of <strong>depleting asparagine</strong>, which is <strong>essential for the survival of ALL cells</strong>. This makes it a <strong>key component</strong> of <strong>chemotherapy regimens</strong> for <strong>ALL,</strong> especially in<strong> pediatric patients</strong>, where it can be <strong>combined with other drugs</strong> to enhance <strong>treatment efficacy and </strong>manage the <strong>disease effectively.</strong></span></span></span></p>",
    "correct_choice_id": 43582,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 10897,
    "choices": [
      {
        "id": 43554,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vinblastine</span></span></span></p>"
      },
      {
        "id": 43555,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
      },
      {
        "id": 43556,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mithramycin</span></span></span></p>"
      },
      {
        "id": 43557,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adriamycin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old male presents with a cough, shortness of breath, and chest pain. Imaging studies reveal a mass in the lung, and a biopsy confirms the diagnosis of carcinoma lung. The patient has a history of chronic obstructive pulmonary disease (COPD) and bronchiectasis. He is currently on bronchodilators, inhaled corticosteroids, and oxygen therapy. The oncologist recommends chemotherapy for the treatment of the cancer. Which of the following drugs should be avoided in this patient?</span></span></span></p>",
    "unique_key": "Q5725673",
    "question_audio": null,
    "question_video": null,
    "map_id": 36451,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong>, an<strong> antineoplastic agent, </strong>is <strong>widely used </strong>to treat <strong>lung cancer, lymphomas, and other cancers.</strong> Its significant<strong> side effect</strong> of <strong>pulmonary toxicity,</strong> which may present as<strong> interstitial pneumonitis or pulmonary fibrosis, </strong>is particularly<strong> dangerous </strong>in patients with <strong>pre-existing lung </strong>conditions such as<strong> COPD and bronchiectasis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Given the patient&#39;s<strong> respiratory history and ongoing lung challenges</strong>, the <strong>risk </strong>of<strong> exacerbating pulmonary symptoms</strong> or inducing further <strong>lung damage</strong> makes <strong>Bleomycin a poor choice.</strong> This<strong> heightened sensitivity</strong> to<strong> lung-related side effects</strong> necessitates the <strong>avoidance of Bleomycin</strong> in favor of other <strong>chemotherapeutic agents</strong> <strong>less likely </strong>to affect <strong>pulmonary function.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Vinblastine:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While Vinblastine can have its own set of <strong>side effect</strong>s, including<strong> bone marrow suppression</strong> and <strong>neurotoxicity</strong>, it <strong>does not </strong>specifically <strong>exacerbate lung </strong></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>conditions</strong> like <strong>COPD or bronchiectasis,</strong> making it a<strong> safer</strong> option than Bleomycin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mithramycin:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This drug is used in the treatment of <strong>testicular cancer </strong>and<strong> certain types</strong> of<strong> hypercalcemia</strong> but is<strong> less</strong> commonly associated with <strong>pulmonary complications,</strong> making it a potentially <strong>safer option </strong>for this patient.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Adriamycin (Doxorubicin):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Adriamycin is known for its <strong>cardiotoxicity rather than pulmonary toxicity,</strong> and therefore, it <strong>does not pose</strong> the same specific <strong>risk to patients with pre-existing lung diseases as Bleomycin</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with<strong> pre-existing lung </strong>conditions such as <strong>COPD and bronchiectasis, Bleomycin</strong> should be<strong> avoided </strong>due to its<strong> potential to</strong> cause significant <strong>pulmonary toxicity.</strong></span></span></span></p>",
    "correct_choice_id": 43555,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 10933,
    "choices": [
      {
        "id": 43698,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Actinomycin</span></p>"
      },
      {
        "id": 43699,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Doxorubicin</span></p>"
      },
      {
        "id": 43700,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Bleomycin</span></p>"
      },
      {
        "id": 43701,
        "text": "<p><span style=\"font-size:18px;\">Mitomycin C</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:14.0pt;\">After 15 days of chemotherapy, a patient develops rash and itching on the back as shown in the image. It can occur as a side effect of which of the following drugs?&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/415.jpg\" alt=\"\" width=\"250\" height=\"348\"></span></p>",
    "unique_key": "Q3499495",
    "question_audio": null,
    "question_video": null,
    "map_id": 36471,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Ans. C) Bleomycin</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Bleomycin</strong> is a<strong> chemotherapeutic agent</strong> that is known to cause a <strong>distinctive pattern of skin pigmentation</strong> called <strong>\"flagellate pigmentation\".</strong> This pattern is characterized by <strong>linear streaks of hyperpigmentation </strong>that resemble the<strong> tracks left by a whip, </strong>or <strong>flagellum.</strong> This reaction is<strong> more</strong> commonly seen in<strong> women</strong> and can <strong>occur several weeks to months</strong> after <strong>starting therapy. </strong>The pigmentation <strong>usually resolves spontaneously</strong>,<strong> but</strong> in some cases, it <strong>can persist for several months to years </strong>after <strong>stopping the</strong> <strong>medication.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option A. Actinomycin:&nbsp;</strong>While actinomycin can cause <strong>side effects</strong> including <strong>nausea and myelosuppression,</strong> it is <strong>not</strong> typically associated with <strong>flagellate pigmentation.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option B. Doxorubicin:&nbsp;</strong>Doxorubicin's <strong>side effect</strong> profile includes<strong> cardiotoxicity and myelosuppression</strong>; <strong>flagellate pigmentation</strong> is<strong> not</strong> a common reaction with <strong>this drug.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Option D. Mitomycin C:&nbsp;</strong>This <strong>chemotherapeutic agent </strong>is more commonly associated with <strong>bone marrow suppression and renal</strong> <strong>toxicity, not</strong> the distinctive<strong> skin pigmentation</strong> seen with <strong>Bleomycin.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Flagellate pigmentation</strong> is a <strong>distinctive cutaneous side effect</strong> associated with <strong>Bleomycin therapy.</strong></span></p>",
    "correct_choice_id": 43700,
    "solution_audio": null,
    "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/10933/FMGE_20_Sep_2025_PHARMACOLOGY_Question_13.mp4",
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "top",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 10903,
    "choices": [
      {
        "id": 43578,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mitoxantrone </span></span></span></p>"
      },
      {
        "id": 43579,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topotecan</span></span></span></p>"
      },
      {
        "id": 43580,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel </span></span></span></p>"
      },
      {
        "id": 43581,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daunorubicin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following drugs acts specifically on the M phase of the cell cycle?</span></span></span></p>",
    "unique_key": "Q2317996",
    "question_audio": null,
    "question_video": null,
    "map_id": 36454,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Paclitaxel</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Paclitaxel </strong>is a <strong>chemotherapy agent</strong> that falls under the<strong> category of taxanes,</strong> which are known for their ability to<strong> inhibit the</strong> <strong>depolymerization of tubulin</strong>. <strong>Tubulin </strong>is a key<strong> protein</strong> involved in <strong>spindle formation</strong> during the<strong> M phase of the cell cycle.</strong> By <strong>stabilizing tubulin polymers,</strong> <strong>paclitaxel effectively </strong>prevents the<strong> spindle fibers from breaking down,</strong> which is essential for<strong> cell</strong> <strong>division.</strong> This <strong>inhibition locks the cells </strong>in the<strong> M phase</strong>, <strong>preventing </strong>them from <strong>successfully completing mitosis</strong>, thus<strong> inhibiting cell</strong> <strong>division and proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mitoxantrone:</span></strong><span style=\"font-size:12.0pt\"> This drug is a <strong>type of antitumor antibiotic </strong>that interferes with<strong> DNA replication and RNA synthesis</strong> but <strong>does</strong> <strong>not </strong>specifically act on the<strong> M phase</strong>. It is classified among<strong> topoisomerase inhibitors</strong> and is used primarily for <strong>its action</strong> in various <strong>phases of the cell cycle,</strong> but <strong>not </strong>specifically the <strong>M phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Topotecan:</span></strong><span style=\"font-size:12.0pt\"> As a<strong> topoisomerase inhibitor, </strong>Topotecan <strong>interferes</strong> with the <strong>ability of topoisomerases</strong> to <strong>relieve torsional</strong> <strong>strain on DNA during replication </strong>and<strong> transcription</strong>. It is <strong>primarily active</strong> in the<strong> S phase of the cell cycle</strong>, not the M phase.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Daunorubicin:</span></strong><span style=\"font-size:12.0pt\"> Another antitumor antibiotic,<strong> Daunorubicin</strong> is involved in <strong>intercalating DNA</strong> and<strong> inhibiting the enzyme</strong> <strong>topoisomerase II,</strong> which <strong>prevents the relaxation of supercoiled DNA and promotes DNA breakage </strong>during <strong>replication</strong>. Like <strong>Mitoxantrone</strong>, it <strong>does not</strong> specifically <strong>target the M phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-121414.png\" style=\"height:454px; width:1000px\" /></span></u></strong></span></span></p>",
    "correct_choice_id": 43580,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10895,
    "choices": [
      {
        "id": 43546,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anthracyclines </span></span></span></p>"
      },
      {
        "id": 43547,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alkylating agents </span></span></span></p>"
      },
      {
        "id": 43548,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platinum compounds </span></span></span></p>"
      },
      {
        "id": 43549,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bisphosphonates</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old woman named Hema has locally advanced breast cancer and has been recommended for chemotherapy. She has a history of myocardial infarction and congestive heart failure. Which antineoplastic drug should be avoided in her treatment?</span></span></span></p>",
    "unique_key": "Q3692302",
    "question_audio": null,
    "question_video": null,
    "map_id": 36450,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Anthracyclines</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Anthracyclines,</strong> such as <strong>doxorubicin, daunorubicin, idarubicin, and epirubicin,</strong> are commonly used in the treatment of<strong> breast cancer.</strong> However, they should be <strong>avoided in Hema&#39;s case</strong> due to their <strong>known association with cardiotoxicity,</strong> which can be especially <strong>hazardous for patients</strong> with <strong>existing heart conditions</strong> like <strong>myocardial infarction</strong> and <strong>congestive heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Anthracyclines</strong> can exacerbate these conditions by <strong>causing left ventricular dysfunction, arrhythmias, and heart failure.</strong> The <strong>cardiotoxicity from anthracyclines </strong>is primarily due to the generation of <strong>iron-mediated free radicals</strong>. <strong>Dexrazoxane</strong> is sometimes used as a <strong>free radical scavenger </strong>to <strong>prevent this cardiotoxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alkylating agents:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect</strong> because while<strong> alkylating agents </strong>are used in<strong> breast cancer treatment</strong>, they are <strong>not </strong>specifically associated with <strong>increased risk of cardiotoxicity, </strong>which is<strong> Hema&#39;s primary</strong> concern given her<strong> cardiac history.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Platinum compounds:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>as <strong>platinum compounds, </strong>commonly used in <strong>various cancers </strong>including <strong>breast cancer,</strong> do <strong>not</strong> have a <strong>direct link to cardiotoxicity</strong> that would particularly <strong>exacerbate Hema&rsquo;s existing heart conditions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bisphosphonates:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect</strong> because <strong>bisphosphonates </strong>are <strong>not</strong> primarily<strong> antineoplastic drugs</strong> but are used to manage <strong>bone metastases </strong>and <strong>prevent bone loss in cancer patients</strong> undergoing<strong> hormonal therapy. </strong>They <strong>do not</strong> pose a <strong>risk of cardiotoxicity,</strong> though they have <strong>other side effects </strong>like <strong>renal dysfunction and osteonecrosis of the jaw.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For a patient with a <strong>history of heart disease</strong>, it is crucial to<strong> avoid anthracyclines </strong>due to their potential to <strong>cause severe cardiotoxicity.</strong> <strong>Alternative chemotherapy </strong>agents <strong>should be </strong>considered that <strong>do not exacerbate heart conditions.</strong></span></span></span></p>",
    "correct_choice_id": 43546,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 10894,
    "choices": [
      {
        "id": 43542,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folinic acid enhances the action of methotrexate</span></span></span></p>"
      },
      {
        "id": 43543,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate acts by inhibiting dihydrofolate reductase</span></span></span></p>"
      },
      {
        "id": 43544,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-proliferative cells are relatively resistant to methotrexate</span></span></span></p>"
      },
      {
        "id": 43545,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate can be used in the treatment of psoriasis</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the following statements about methotrexate are correct except:</span></span></span></p>",
    "unique_key": "Q2972366",
    "question_audio": null,
    "question_video": null,
    "map_id": 36449,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Folinic acid enhances the action of methotrexate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The statement is<strong> incorrect </strong>because<strong> folinic acid (leucovorin)</strong> is actually used to <strong>mitigate the toxic effects of methotrexate</strong>, particularly when<strong> administered in high doses. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Folinic acid</strong> provides a means of &quot;<strong>rescue&quot;</strong> by supplementing the body with a <strong>form of folate</strong> that<strong> does not </strong>require activation by <strong>dihydrofolate reductase (DHFRase)</strong>, thus allowing for <strong>normal cellular functions </strong>to continue despite<strong> methotrexate&#39;s inhibition</strong> of the enzyme.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methotrexate acts by inhibiting dihydrofolate reductase:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>correct</strong>. Methotrexate is an<strong> anti-metabolite</strong> that <strong>inhibits DHFRase, reducing</strong> the formation of<strong> tetrahydrofolate </strong>required for<strong> purine and thymidylate synthesis</strong>, which are essential for<strong> DNA replication and cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Non-proliferative cells are relatively resistant to methotrexate:</span></strong><span style=\"font-size:12.0pt\"> This is <strong>correct.</strong> Methotrexate&#39;s mechanism targets the<strong> S-phase of the cell cycle, </strong>affecting <strong>rapidly dividing cells;</strong> thus, cells that are in a <strong>resting state show relative resistance.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Methotrexate can be used in the treatment of psoriasis:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>true</strong>. Beyond its oncological applications, methotrexate is used as a<strong> first-line disease-modifying anti-rheumatic drug (DMARD) </strong>and is <strong>effective</strong> for conditions like<strong> psoriasis and</strong> <strong>ectopic pregnancy</strong> due to its <strong>anti-proliferative effects </strong>on <strong>fast-dividing cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate </strong>is a <strong>critical drug</strong> used for a variety of conditions, including as the <strong>drug of choice for choriocarcinoma</strong> and a <strong>first-line</strong> <strong>DMARD</strong>. It is <strong>essential</strong> to understand that while<strong> methotrexate inhibits DHFRase,</strong> leading to<strong> decreased DNA synthesis </strong>in <strong>proliferating cells, folinic acid </strong>is used to<strong> rescue normal cells </strong>from its<strong> toxic effects, not</strong> enhance its <strong>action.</strong></span></span></span></p>",
    "correct_choice_id": 43542,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10912,
    "choices": [
      {
        "id": 43614,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cladribine</span></span></span></p>"
      },
      {
        "id": 43615,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gemcitabine</span></span></span></p>"
      },
      {
        "id": 43616,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Capecitabine</span></span></span></p>"
      },
      {
        "id": 43617,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients undergoing treatment for colorectal cancer have developed symptoms such as tingling, numbness, pain, and erythema on the palms and soles of their feet as shown in the figure below. Which of the following chemotherapy drugs could be the causative agent?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/403_RU0SYwK.jpg\" style=\"height:280px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q9876037",
    "question_audio": null,
    "question_video": null,
    "map_id": 36457,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Capecitabine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The symptoms described &ndash; <strong>tingling, numbness, pain, and erythema</strong> on the <strong>palms and soles </strong>&ndash; are<strong> indicative </strong>of a condition <strong>known as</strong> <strong>hand-foot syndrome</strong> or <strong>palmar-plantar erythrodysesthesia</strong>. This condition is a <strong>known side effect </strong>of certain <strong>chemotherapy drugs</strong>. Among the options given, the <strong>drug</strong> most likely to <strong>cause</strong> these symptoms in patients<strong> undergoing treatment for colorectal cancer</strong> is <strong>capecitabine</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Capecitabine</strong> is an <strong>oral prodrug of 5-fluorouracil (5-FU)</strong> and is commonly used in the treatment of <strong>colorectal cancer.</strong> <strong>Hand-foot</strong> <strong>syndrome </strong>is a <strong>well-known </strong>and <strong>relatively common</strong> side effect of <strong>capecitabine,</strong> characterized by <strong>redness, swelling, pain, </strong>and <strong>numbness</strong> in the <strong>palms of the hands and soles of the feet.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Cladribine</strong>: Primarily<strong> used</strong> in<strong> hairy cell leukemia,</strong> <strong>cladribine</strong> can cause <strong>several side effects</strong> but is <strong>not </strong>typically associated with<strong> hand-foot syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> <strong>Gemcitabine</strong>: Used in<strong> various cancers</strong>, including <strong>pancreatic, breast, and non-small cell lung cancer</strong>. While <strong>gemcitabine </strong>has many<strong> side effects,</strong> it is<strong> less</strong> commonly associated with<strong> hand-foot syndrome</strong> compared to<strong> capecitabine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Bleomycin</strong>: Used in the <strong>treatment of Hodgkin&#39;s lymphoma</strong>, <strong>testicular cancer,</strong> and<strong> other types of cancer. Bleomycin</strong> is <strong>more </strong>known for<strong> pulmonary side effects,</strong> and<strong> hand-foot syndrome</strong> is<strong> not</strong> a <strong>typical side effect of this drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Capecitabine</strong> is the likely cause of the symptoms due to its <strong>known </strong>association with<strong> hand-foot syndrome</strong>, particularly in patients treated for<strong> colorectal cancer.</strong></span></span></span></p>",
    "correct_choice_id": 43616,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 10893,
    "choices": [
      {
        "id": 43538,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is metabolized by cytochrome p450 enzymes</span></span></span></p>"
      },
      {
        "id": 43539,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is less neurotoxic than cyclophosphamide</span></span></span></p>"
      },
      {
        "id": 43540,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chloroacetaldehyde is the metabolite of ifosfamide</span></span></span></p>"
      },
      {
        "id": 43541,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is an alkylating agent</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the following statements are true regarding ifosfamide except?</span></span></span></p>",
    "unique_key": "Q4625536",
    "question_audio": null,
    "question_video": null,
    "map_id": 36448,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Less neurotoxic than cyclophosphamide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>correct</strong> statement that is <strong>false</strong> about <strong>ifosfamide</strong> is that it is <strong>less neurotoxic than cyclophosphamide.</strong> In fact,<strong> ifosfamide</strong> is associated with<strong> greater neurotoxicity</strong> compared <strong>to cyclophosphamide.</strong> This is a critical consideration in clinical settings, as <strong>ifosfamide&#39;s neurotoxic effects</strong> can<strong> limit its dosage </strong>and r<strong>equire careful monitoring.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It is metabolized by cytochrome p450 enzymes:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>true.</strong> <strong>Ifosfamide</strong>, like many other <strong>alkylating agents</strong> including <strong>cyclophosphamide</strong>, is metabolized by<strong> cytochrome p450 enzymes, </strong>which play a key role in its<strong> activation and detoxification.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chloroacetaldehyde is the metabolite of ifosfamide:</span></strong><span style=\"font-size:12.0pt\"> This is also<strong> true</strong>. The metabolism of<strong> ifosfamide</strong> involves the <strong>production of chloroacetaldehyde</strong>, a <strong>metabolite</strong> that contributes to<strong> its nephrotoxic effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It is an alkylating agent:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>correct</strong>. <strong>Ifosfamide</strong> belongs to the <strong>nitrogen mustard group of alkylating agents,</strong> which are used in <strong>cancer chemotherapy</strong> to <strong>alkylate the DNA of cancer cells</strong>, leading to <strong>cell death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ifosfamide, </strong>while being a valuable <strong>chemotherapeutic alkylating agent</strong>, carries a significant <strong>risk of neurotoxicity</strong> that is <strong>greater than</strong> that of <strong>cyclophosphamide. </strong>This fact must be <strong>carefully considered </strong>when <strong>prescribing and managing treatment with ifosfamide </strong>in clinical practice.</span></span></span></p>",
    "correct_choice_id": 43539,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10898,
    "choices": [
      {
        "id": 43558,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chlorambucil</span></span></span></p>"
      },
      {
        "id": 43559,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin</span></span></span></p>"
      },
      {
        "id": 43560,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin</span></span></span></p>"
      },
      {
        "id": 43561,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daunorubicin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common side effect of cancer chemotherapy is nausea with or without vomiting. The anticancer drugs vary is their ability to cause nausea and vomiting. Which of the following anti-cancer drugs is least likely to cause nausea and vomiting?</span></span></span></p>",
    "unique_key": "Q8766742",
    "question_audio": null,
    "question_video": null,
    "map_id": 36452,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Chlorambucil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Chlorambucil</strong> is an<strong> alkylating agent</strong> typically used in the treatment of <strong>chronic lymphocytic leukemia</strong> and other <strong>hematological</strong> <strong>malignancies.</strong> Compared to the other drugs listed, <strong>chlorambucil</strong> has a<strong> lower emetogenic potential</strong>, meaning it is <strong>less likely</strong> to cause <strong>nausea and vomiting.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cisplatin and cyclophosphamide </strong>have v<strong>ery high emetogenic potential </strong>whereas <strong>chlorambucil and busulfan</strong> have the <strong>least. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cisplatin:</span></strong><span style=\"font-size:12.0pt\"> Known for its<strong> high emetogenic potential,</strong> cisplatin is a <strong>platinum-based drug </strong>that often requires <strong>premedication</strong> <strong>with antiemetics </strong>to manage its <strong>severe nausea and vomiting</strong> side effects.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Doxorubicin:</span></strong><span style=\"font-size:12.0pt\"> As an<strong> anthracycline, doxorubicin</strong> has a <strong>moderate to high emetogenic potential</strong>, necessitating the <strong>use of</strong> <strong>antiemetics</strong> for patient <strong>comfort during treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Daunorubicin:</span></strong><span style=\"font-size:12.0pt\"> <strong>Similar</strong> in class to <strong>doxorubicin</strong>, <strong>daunorubicin</strong> also has a<strong> moderate to high emetogenic risk, </strong>which can affect patient<strong> quality of life and treatment adherence.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When considering the <strong>side effect </strong>profile of <strong>chemotherapeutic agents,</strong> especially regarding <strong>emesis,</strong> <strong>chlorambucil </strong>is noted for its <strong>lower likelihood </strong>of causing <strong>nausea and vomiting </strong>relative to other agents like <strong>cisplatin, doxorubicin, and daunorubicin. </strong></span></span></span></p>",
    "correct_choice_id": 43558,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10899,
    "choices": [
      {
        "id": 43562,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folinic acid and vitamin B6</span></span></span></p>"
      },
      {
        "id": 43563,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folic acid and vitamin B12</span></span></span></p>"
      },
      {
        "id": 43564,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B6 and vitamin B12</span></span></span></p>"
      },
      {
        "id": 43565,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folic acid and dexamethasone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following medications is essential for ameliorating the toxicity of pemetrexed?</span></span></span></p>",
    "unique_key": "Q7815960",
    "question_audio": null,
    "question_video": null,
    "map_id": 36453,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Folic acid and vitamin B12</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pemetrexed </strong>is a <strong>chemotherapy agent </strong>primarily used to <strong>treat lung cancer and mesothelioma.</strong> A <strong>major side effect</strong> of pemetrexed is <strong>myelosuppression</strong>, which can lead to serious<strong> blood-related issues </strong>such as <strong>anemia, neutropenia, and thrombocytopenia.</strong> To <strong>counteract this toxicity</strong>, supplementation with<strong> folic acid and vitamin B12 </strong>is recommended. <strong>Folic acid </strong>helps maintain necessary levels of <strong>folate within cells</strong>, aiding in<strong> DNA and RNA synthesis </strong>which are crucial <strong>during cell division. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pemetrexed interferes</strong> with<strong> folate metabolism by inhibiting</strong> key <strong>enzymes</strong>; therefore, <strong>folic acid supplementation</strong> is vital to <strong>mitigate</strong> this effect. Similarly,<strong> vitamin B12 plays a critical role in DNA synthesis </strong>and <strong>red blood cell maturation. Supplementation with vitamin</strong> <strong>B12 </strong>helps <strong>prevent deficiencies</strong> that can <strong>exacerbate anemia </strong>and other <strong>hematological issues</strong> caused by <strong>pemetrexed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Folinic acid and vitamin B6:</span></strong><span style=\"font-size:12.0pt\"> This combination is<strong> incorrect as folinic acid,</strong> while related to folate, is <strong>not </strong>used to mitigate the toxicity associated with pemetrexed, and <strong>vitamin B6 does not</strong> play a role in <strong>mitigating pemetrexed&#39;s specific toxic effects</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vitamin B6 and vitamin B12:</span></strong><span style=\"font-size:12.0pt\"> Vitamin B12 is <strong>correct</strong> in part; however,<strong> vitamin B6</strong> <strong>does not</strong> aid in <strong>ameliorating </strong>the <strong>specific</strong> <strong>toxicities of pemetrexed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Folic acid and dexamethasone:</span></strong><span style=\"font-size:12.0pt\"> While<strong> folic acid </strong>is a <strong>correct component</strong>,<strong> dexamethasone </strong>is primarily used for its <strong>anti-inflammatory properties </strong>and <strong>not for</strong> <strong>mitigating myelosuppression</strong> caused by<strong> pemetrexed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For<strong> patients</strong> undergoing<strong> treatment with pemetrexed</strong>, it is <strong>crucial to supplement</strong> with <strong>folic acid and vitamin B12</strong> to <strong>reduce the risk of</strong> <strong>myelosuppression </strong>and related <strong>complications. </strong>This supplementation strategy helps <strong>maintain necessary folate and vitamin B12</strong> <strong>levels</strong>, <strong>supporting DNA synthesis and red blood cell maturation</strong>, thereby<strong> counteracting the drug&#39;s </strong>potential <strong>hematological toxicities.</strong></span></span></span></p>",
    "correct_choice_id": 43563,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 10906,
    "choices": [
      {
        "id": 43590,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chlorambucil</span></span></span></p>"
      },
      {
        "id": 43591,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate</span></span></span></p>"
      },
      {
        "id": 43592,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine</span></span></span></p>"
      },
      {
        "id": 43593,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 60-year-old patient with non-Hodgkin&#39;s lymphoma is undergoing chemotherapy. The oncologist discusses the mechanism of action of various chemotherapeutic agents to optimize the patient&#39;s treatment regimen. Understanding the specific phases of the cell cycle that these drugs target is crucial for effective therapy.&nbsp;Which of the following chemotherapeutic agents acts predominantly during the S phase of the cell cycle?</span></span></span></p>",
    "unique_key": "Q9245504",
    "question_audio": null,
    "question_video": null,
    "map_id": 36456,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Methotrexate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> is a <strong>chemotherapeutic agent </strong>that acts as a<strong> folate analog to inhibit the enzyme dihydrofolate reductase. </strong>This enzyme is<strong> essential for the synthesis of tetrahydrofolate,</strong> a molecule necessary for the<strong> production of thymidine and purine nucleotides,</strong> which are <strong>required for DNA synthesis.</strong> Since DNA synthesis is a critical activity during the<strong> S phase of the cell cycle,</strong> <strong>methotrexate</strong> primarily exerts its<strong> cytotoxic effects in this phase</strong>, making it particularly <strong>effective against rapidly dividing cells</strong> such as those found in <strong>various cancers.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Chlorambucil</strong>: This is an<strong> </strong><strong>alkylating agent</strong> that <strong>acts</strong> primarily in the <strong>G1 and S phases,</strong> but it&#39;s <strong>not as specific </strong>to the<strong> S phase</strong> compared to<strong> some other drugs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Vincristine</strong>: Vincristine is a<strong> mitotic inhibitor </strong>that primarily <strong>acts</strong> on the <strong>M phase of the cell cycle</strong>. It <strong>inhibits microtubule</strong> <strong>formation, </strong>which is <strong>crucial for cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Paclitaxel</strong>: Paclitaxel is also a<strong> mitotic inhibitor </strong>that <strong>acts </strong>mainly on the<strong> M phase.</strong> It<strong> stabilizes microtubules,</strong> <strong>preventing </strong>their <strong>disassembly,</strong> which is necessary for <strong>cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate&#39;s</strong> specific action of<strong> inhibiting DNA synthesis </strong>during the <strong>S phase.</strong></span></span></span></p>",
    "correct_choice_id": 43591,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 43254,
    "choices": [
      {
        "id": 172683,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chlorambucil </span></span></span></p>"
      },
      {
        "id": 172684,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
      },
      {
        "id": 172685,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine </span></span></span></p>"
      },
      {
        "id": 172686,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old woman with breast cancer is undergoing chemotherapy. She is currently receiving a drug that acts on the &#39;S&#39; phase of the cell cycle. Which of the following drugs is most likely being used in her treatment?</span></span></span></p>",
    "unique_key": "Q9224287",
    "question_audio": null,
    "question_video": null,
    "map_id": 36475,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Methotrexate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate </strong>is a well-known <strong>chemotherapeutic agent</strong> that specifically targets the<strong> S phase of the cell cycle</strong>, which is the phase in which<strong> DNA synthesis occurs.</strong> It acts by<strong> inhibiting dihydrofolate reductase,</strong> an enzyme critical for the<strong> synthesis of tetrahydrofolate,</strong> necessary for the <strong>production of thymidylate and purine nucleotides</strong>&mdash;both <strong>essential </strong>components for <strong>DNA replication</strong> and <strong>cell</strong> <strong>division</strong>. This specific mechanism makes<strong> Methotrexate</strong> particularly <strong>effective during the S phase,</strong> where it can <strong>inhibit the growth of</strong> <strong>cancer cells </strong>by preventing<strong> DNA replication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chlorambucil:</span></strong><span style=\"font-size:12.0pt\"> This drug is an <strong>alkylating agent</strong> that is<strong> not </strong>specific to any<strong> particular phase of the cell cycle</strong>. It can form <strong>cross-links in DNA</strong> <strong>at any phase</strong>, thereby causing <strong>damage</strong> that leads to<strong> cell death.</strong> While effective <strong>against various cancers, </strong>it <strong>does</strong> <strong>not</strong> specifically target the<strong> S phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vincristine:</span></strong><span style=\"font-size:12.0pt\"> Vincristine is a<strong> vinca alkaloid</strong> that acts predominantly during the <strong>M phase of the cell cycle. </strong>It<strong> inhibits</strong> <strong>microtubule formation</strong>, which is essential for <strong>mitotic spindle</strong> assembly and <strong>chromosome</strong> separation during <strong>mitosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Paclitaxel:</span></strong><span style=\"font-size:12.0pt\"> Also acting in the<strong> M phase,</strong> Paclitaxel stabilizes <strong>microtubules </strong>and <strong>prevents </strong>their <strong>disassembly, </strong>thus<strong> inhibiting</strong> the <strong>completion of mitosis </strong>and <strong>leading to cell death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> is a<strong> cell cycle-specific anticancer drug </strong>that acts by <strong>inhibiting DNA synthesis</strong> in the<strong> &#39;S&#39; phase</strong> of the cell cycle. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Chlorambucil</strong> is a <strong>cell cycle-nonspecific alkylating agent </strong>that can affect cells in <strong>any phase of the cell cycle. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vincristine and Paclitaxel </strong>are<strong> cell cycle-specific anticancer drug </strong>that acts in the<strong> &#39;M&#39; phase of the cell cycle.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 172684,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 10913,
    "choices": [
      {
        "id": 43618,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X is 5-Fluorourcail, and Y is Methotrexate</span></span></span></p>"
      },
      {
        "id": 43619,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X is Methotrexate and Y is 5-Fluorouracil</span></span></span></p>"
      },
      {
        "id": 43620,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X is Vincristine and Y is Methotrexate</span></span></span></p>"
      },
      {
        "id": 43621,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both X and Y are methotrexate</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mechanism of action of two anticancer drugs X and Y is shown in the figure below. Which of following statements most correctly represent drug X and Y?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/404.jpg\" style=\"height:505px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q8710912",
    "question_audio": null,
    "question_video": null,
    "map_id": 36458,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) X is Methotrexate and Y is 5-Fluorouracil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> <strong>inhibits</strong> <strong>dihydrofolate reductase (DHFRase),</strong> an <strong>enzyme</strong> that is involved in the <strong>synthesis of nucleotides</strong>. By <strong>inhibiting DHFRase</strong>, methotrexate<strong> prevents the formation of tetrahydrofolate</strong>, which is required for the <strong>synthesis of</strong> <strong>thymidylate, purines, and other nucleotides.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>5-Fluorouracil (5-FU)</strong>, on the other hand, <strong>inhibits thymidylate synthase</strong>, an enzyme that is required for the <strong>synthesis of</strong> <strong>thymidylate</strong>, which is essential for <strong>DNA replication. </strong>By <strong>inhibiting thymidylate synthase,</strong> <strong>5-FU reduces </strong>the production of <strong>thymidylate </strong>and thereby <strong>inhibits DNA synthesis.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. X is 5-Fluorouracil, and Y is Methotrexate:</span></strong><span style=\"font-size:12.0pt\"> This is<strong> incorrect </strong>because <strong>5-FU does not inhibit DHFR </strong>but <strong>inhibits thymidylate</strong> <strong>synthase,</strong> and <strong>Methotrexate inhibits DHFR</strong>, <strong>not thymidylate synthase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>X is Vincristine and Y is Methotrexate: Vincristine</strong> is a <strong>microtubule inhibitor</strong> that<strong> blocks cell division </strong>by <strong>inhibiting the</strong> formation of the <strong>mitotic spindle</strong>. It<strong> does not</strong> <strong>inhibit</strong> thymidylate<strong> synthase or DHFRase.</strong> Therefore, <strong>option C is incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Both X and Y are methotrexate:</span></strong><span style=\"font-size:12.0pt\"> is also<strong> incorrect</strong> because <strong>both X and Y cannot be methotrexate,</strong> as they have <strong>different</strong> <strong>targets of action.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate (Drug X) inhibits</strong> the enzyme<strong> DHFR,</strong> essential for<strong> DNA nucleotide synthesis,</strong> while<strong> 5-Fluorouracil (Drug Y) inhibits</strong> <strong>thymidylate synthase,</strong> critical for the <strong>production of the thymidine nucleotide</strong> necessary for<strong> DNA synthesis. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding these targets is key to <strong>recognizing</strong> the rationale behind using<strong> these drugs </strong>in the treatment of <strong>cancers like leukemia</strong> and<strong> colorectal cancer, respectively.</strong></span></span></span></p>",
    "correct_choice_id": 43619,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 10915,
    "choices": [
      {
        "id": 43626,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of microtubule polymerization </span></span></span></p>"
      },
      {
        "id": 43627,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of DNA synthesis </span></span></span></p>"
      },
      {
        "id": 43628,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of DNA topoisomerase II </span></span></span></p>"
      },
      {
        "id": 43629,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of tyrosine kinase activity</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old woman presents with a diagnosis of non-Hodgkin&#39;s lymphoma. She is started on chemotherapy, which includes a drug derived from the periwinkle plant (Image shown below). Which of the following is the mechanism of action of this drug?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/406.jpg\" style=\"height:239px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q8659474",
    "question_audio": null,
    "question_video": null,
    "map_id": 36459,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Inhibition of microtubule polymerization</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> drugs derived</strong> <strong>from</strong> the <strong>periwinkle plant </strong>are <strong>vincristine and vinblastine.</strong> These belongs to the <strong>class of drugs</strong> known as <strong>vinca</strong> <strong>alkaloids</strong>. These act by<strong> inhibiting microtubule polymerization</strong>, which <strong>disrupts the formation of the mitotic spindle</strong> during<strong> cell</strong> <strong>division,</strong> leading to<strong> cell cycle arrest and apoptosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Doxorubicin and etoposide </strong>work by <strong>inhibiting DNA synthesis</strong> and <strong>DNA topoisomerase II,</strong> respectively, they are <strong>not</strong> <strong>derived from the periwinkle plant. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Inhibition of tyrosine kinase activity</strong> is the<strong> mechanism of action</strong> of drugs such as<strong> imatinib</strong>, which is <strong>drug of choice</strong> for <strong>CML and GIST. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhibition of DNA synthesis:</span></strong><span style=\"font-size:12.0pt\"> While some <strong>chemotherapeutic agents </strong>do <strong>inhibit DNA synthesis,</strong> the<strong> drugs derived </strong>from the <strong>periwinkle plan</strong>t<strong> do not</strong> act through this<strong> mechanism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibition of DNA topoisomerase II:</span></strong><span style=\"font-size:12.0pt\"> This is the <strong>mechanism of action</strong> for drugs like<strong> etoposide</strong>, not vinca alkaloids.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhibition of tyrosine kinase activity:</span></strong><span style=\"font-size:12.0pt\"> Drugs like<strong> imatinib inhibit tyrosine kinase activity</strong> and are used for conditions such as <strong>chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), </strong>which is <strong>not</strong> the mechanism for <strong>vinca alkaloids.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vinca alkaloids,</strong> such as<strong> vincristine and vinblastine</strong>, work by<strong> inhibiting microtubule polymerization, </strong>leading to <strong>disruption of mitotic</strong> <strong>spindle formation,</strong> <strong>cell cycle arrest</strong>, and<strong> ultimately apoptosis</strong>. This mechanism is<strong> distinct </strong>and <strong>should no</strong>t be confused with drugs that<strong> inhibit DNA synthesis, DNA topoisomerase II,</strong> or<strong> tyrosine kinase activity.</strong></span></span></span></p>",
    "correct_choice_id": 43626,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 10917,
    "choices": [
      {
        "id": 43634,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Stabilizes microtubules and prevent depolymerization</span></p>"
      },
      {
        "id": 43635,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Used in ovarian, cervix and breast cancer</span></p>"
      },
      {
        "id": 43636,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Most commonly causes myelosuppression and alopecia</span></p>"
      },
      {
        "id": 43637,
        "text": "<p><span style=\"font-size:12.0pt;\">Obtained from E. coli</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">All the following are true about paclitaxel except:</span></p>",
    "unique_key": "Q4211879",
    "question_audio": null,
    "question_video": null,
    "map_id": 36460,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D) Obtained from E. coli</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Paclitaxel </strong>is a<strong> chemotherapy </strong>drug that<strong> stabilizes microtubules </strong>and <strong>prevents their depolymerization,</strong> leading to<strong> cell</strong> <strong>cycle arrest and apoptosis.</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It is <strong>commonly used</strong> in the treatment of<strong> ovarian, cervical, and breast cancer</strong>, among others.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Like <strong>most cytotoxic drugs, Paclitaxel</strong> is also known to cause <strong>myelosuppression and alopecia (hair loss)</strong> as common side effects.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">However, <strong>Paclitaxel</strong> is <strong>not</strong> obtained from<strong> E. coli</strong>. It is originally derived from the <strong>bark of the Pacific yew tree,</strong> <strong>Taxus</strong> <strong>brevifolia</strong>, and is now produced<strong> synthetically or through semi-synthesis.</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A. Stabilizes microtubules and prevent polymerization:</strong> The statement is almost <strong>correct</strong> but has a <strong>crucial error. Paclitaxel</strong> <strong>actually stabilizes microtubules</strong> but <strong>prevents </strong>their <strong>depolymerization, not polymerization.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B. Used in ovarian, cervix and breast cancer:</strong> This is <strong>true.</strong> <strong>Paclitaxel</strong> is<strong> used </strong>in the treatment of these <strong>cancers</strong> due to its <strong>effectiveness in inhibiting cell division.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option C. Most commonly causes myelosuppression and alopecia:</strong> Also <strong>true.</strong> These are <strong>common side effects</strong> of <strong>many</strong> <strong>chemotherapeutic agents</strong>, including<strong> paclitaxel.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Paclitaxel</strong>, a <strong>chemotherapeutic agent</strong> that is<strong> known</strong> for its <strong>ability to stabilize microtubules </strong>and thereby <strong>prevent their</strong> <strong>depolymerization</strong>, leading to <strong>inhibition of cell division</strong> in <strong>cancer treatment. </strong>It is associated with<strong> side effects</strong> such as <strong>myelosuppression and alopecia;</strong> and it was<strong> originally</strong> obtained from the <strong>bark of the Pacific yew tree</strong> and now can be <strong>produced</strong> <strong>synthetically.</strong></span></p>",
    "correct_choice_id": 43637,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10919,
    "choices": [
      {
        "id": 43642,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amifostine</span></span></span></p>"
      },
      {
        "id": 43643,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxyurea</span></span></span></p>"
      },
      {
        "id": 43644,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5FU</span></span></span></p>"
      },
      {
        "id": 43645,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bromodeoxyuridine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which is not a radiosensitizer?</span></span></p>",
    "unique_key": "Q6952089",
    "question_audio": null,
    "question_video": null,
    "map_id": 36461,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Amifostine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&nbsp;Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Amifostine </strong>is classified as a <strong>radioprotective agent</strong> rather than a<strong> radiosensitizer.</strong> It <strong>works</strong> by <strong>protecting normal tissues</strong> from the<strong> toxic</strong> <strong>effects of radiation</strong>. <strong>Amifostine</strong> is a <strong>cytoprotective prodrug</strong> that, <strong>once activated,</strong> has <strong>free radical scavenging properties,</strong> thus <strong>protecting cells</strong> from the <strong>damaging effects of radiation therapy.</strong> It selectively <strong>accumulates in normal cells</strong> over<strong> tumor cells </strong>and, <strong>upon activation</strong>, it <strong>detoxifies reactive oxygen species</strong> and<strong> other radicals</strong> generated by <strong>radiation in normal tissues.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hydroxyurea:</span></strong><span style=\"font-size:12.0pt\"> Hydroxyurea acts as a<strong> radiosensitizer</strong> by<strong> inhibiting the enzyme ribonucleotide reductase,</strong> which leads to a <strong>depletion of deoxyribonucleotides</strong> and thereby<strong> enhances the effects of radiation on cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 5FU (5-Fluorouracil):</span></strong><span style=\"font-size:12.0pt\"> <strong>5FU </strong>is a <strong>chemotherapy agent</strong> that also functions as a <strong>radiosensitizer.</strong> It is <strong>incorporated </strong>into<strong> RNA </strong>and <strong>DNA </strong>and<strong> interfere</strong>s with the <strong>synthesis</strong> and<strong> function of nucleic acids</strong>, <strong>enhancing radiation therapy&#39;s efficacy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bromodeoxyuridine:</span></strong><span style=\"font-size:12.0pt\"> This is a <strong>thymidine analog </strong>that is<strong> incorporated into DNA </strong>during the <strong>S-phase of the cell cycle</strong>, making <strong>DNA more </strong>susceptible to<strong> damage by radiation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">key differences between radiosensitizers and radioprotectors:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-143815.png\" style=\"height:547px; width:1000px\" /></span></strong></span></span></p>",
    "correct_choice_id": 43642,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10920,
    "choices": [
      {
        "id": 43646,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin </span></span></span></p>"
      },
      {
        "id": 43647,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Minocycline </span></span></span></p>"
      },
      {
        "id": 43648,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine </span></span></span></p>"
      },
      {
        "id": 43649,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daunorubicin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 32-year-old female presents to the clinic with a complaint of a rash on her arms and legs that has been present for the past few weeks. She reports feeling fatigued and has been experiencing intermittent fevers. The patient has a history of Hodgkin&#39;s lymphoma and underwent chemotherapy treatment approximately two months ago. Her chemotherapy regimen included daunorubicin, bleomycin, and vincristine. On physical examination, the patient is noted to have multiple erythematous, linear lesions on her arms and legs that appear to be hyperpigmented in a flagellate pattern. The remainder of her examination is unremarkable. Based on the patient&#39;s clinical history and examination, which drug is most likely responsible for her skin pigmentation?</span></span></span></p>",
    "unique_key": "Q1912153",
    "question_audio": null,
    "question_video": null,
    "map_id": 36462,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong> is a <strong>chemotherapeutic agent</strong> that is known to cause a <strong>distinctive pattern of skin pigmentation</strong> called <strong>&quot;flagellate pigmentation.</strong>&quot; This pattern is characterized by<strong> linear streaks of hyperpigmentation</strong> that resemble the tracks <strong>left by a whip, or flagellum</strong>. This reaction is<strong> more </strong>commonly<strong> seen in women </strong>and can occur <strong>several weeks to months</strong> after<strong> starting therapy</strong>. The <strong>pigmentation </strong>usually<strong> resolves spontaneously,</strong> but in some cases, it can <strong>persist for several months to years after stopping the medication.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/409.jpg\" style=\"height:446px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Minocycline:</span></strong><span style=\"font-size:12.0pt\"> This is an <strong>antibiotic</strong> that can cause various types of <strong>skin hyperpigmentation</strong>, but these usually take the form of<strong> blue-gray spots or diffuse pigmentation, particularly </strong>in areas of <strong>previous inflammation or sun exposure</strong>. It is <strong>not </strong>known to cause the<strong> flagellate or whip-like streaking pattern </strong>associated <strong>with Bleomycin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vincristine:</span></strong><span style=\"font-size:12.0pt\"> While<strong> Vincristine</strong> is a<strong> chemotherapeutic agent</strong> used in the <strong>same types of cancer </strong>as<strong> Bleomycin</strong>, its <strong>side effect</strong> profile includes<strong> neurological symptoms</strong> such as <strong>peripheral neuropathy,</strong> rather than <strong>dermatological condition</strong>s like <strong>flagellate</strong> <strong>pigmentation.</strong> The<strong> presentation </strong>of such a <strong>specific skin reaction does not</strong> align with the <strong>known adverse effects of Vincristine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Daunorubicin:</span></strong><span style=\"font-size:12.0pt\"> As an<strong> anthracycline chemotherapeutic</strong>, <strong>Daunorubicin</strong> can cause a<strong> variety of side effects,</strong> with the most <strong>prominent being myelosuppression.</strong> It can also<strong> lead to cardiotoxicity </strong>with <strong>long-term use</strong>. However, it is <strong>not </strong>implicated in causing the characteristic <strong>flagellate pigmentation </strong>that is <strong>seen with Bleomycin therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong> can lead to <strong>flagellate pigmentation</strong>, a <strong>distinct dermatologic reaction </strong>characterized by <strong>whip-like hyperpigmented streaks</strong>. This <strong>adverse effect </strong>should be recognized by<strong> healthcare providers</strong> as a<strong> potential delayed side effect of the drug,</strong> particularly in <strong>patients with a history of cancer </strong>treatment including<strong> Bleomycin.</strong></span></span></span></p>",
    "correct_choice_id": 43646,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 10922,
    "choices": [
      {
        "id": 43654,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alkylation of DNA </span></span></span></p>"
      },
      {
        "id": 43655,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crosslinking of DNA </span></span></span></p>"
      },
      {
        "id": 43656,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microtubule inhibition </span></span></span></p>"
      },
      {
        "id": 43657,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proteosome inhibition</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents to the oncology clinic with a 6-month history of progressively worsening headaches and nausea. He has no significant past medical history. MRI reveals a large, heterogeneously enhancing mass in the right frontal lobe. Biopsy confirms the diagnosis of glioblastoma multiforme. The patient is started on temozolomide. What is the mechanism of action of temozolomide? </span></span></span></p>",
    "unique_key": "Q9845125",
    "question_audio": null,
    "question_video": null,
    "map_id": 36463,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Alkylation of DNA</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Temozolomide</strong> works primarily through the <strong>alkylation of DNA,</strong> where it <strong>methylates guanine residues</strong> at the<strong> O6 and N7 positions</strong>. This <strong>methylation damages the DNA, </strong>leading to <strong>errors in replication </strong>that the cancer cell<strong> cannot repair, </strong>ultimately <strong>triggering cell</strong> <strong>death</strong>. <strong>This mechanism</strong> is particularly<strong> effective</strong> against<strong> rapidly dividing cells</strong>, such as those found in<strong> glioblastoma multiform</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Crosslinking of DNA:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> for temozolomide. <strong>Crosslinking of DNA strands</strong> is characteristic of <strong>platinum-based</strong> <strong>chemotherapeutic</strong> agents such as<strong> cisplatin and carboplatin</strong>, which form <strong>covalent bonds between adjacent guanine bases, </strong>thereby <strong>preventing DNA</strong> from being <strong>unwound for replication or transcription.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Microtubule inhibition:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> for temozolomide. <strong>Microtubule inhibitors</strong> like <strong>paclitaxel and vinblastine</strong> <strong>disrupt</strong> <strong>microtubule dynamics</strong>, which are critical for<strong> cell division</strong>, particularly during<strong> mitosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Proteosome inhibition:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> for temozolomide. <strong>Proteosome inhibitors</strong>, such as <strong>bortezomib and carfilzomib,</strong> <strong>block</strong> the<strong> proteasome&#39;s </strong>role in <strong>degrading misfolded proteins</strong>, which causes an accumulation of <strong>defective proteins </strong>and<strong> induces apoptosis</strong> in <strong>cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Temozolomide&#39;s</strong> mechanism of action as a<strong> DNA alkylating agent </strong>makes it <strong>effective in treating glioblastoma multiforme </strong>by inducing <strong>lethal DNA damage</strong> in the<strong> rapidly dividing tumor cells</strong>. This action highlights the<strong> importance of DNA integrity in cell survival</strong> and the <strong>therapeutic targeting of DNA repair </strong>mechanisms in <strong>cancer treatment.</strong></span></span></span></p>",
    "correct_choice_id": 43654,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 10924,
    "choices": [
      {
        "id": 43662,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mechlorethamine</span></span></span></p>"
      },
      {
        "id": 43663,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oncovin</span></span></span></p>"
      },
      {
        "id": 43664,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Procarbazine</span></span></span></p>"
      },
      {
        "id": 43665,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old male was on treatment with MOPP regimen for Hodgkin&rsquo;s lymphoma. He recently attended a party and had bouts of alcohol with his friends. Soon after, he started experiencing flushing of the face, headache, nausea, vomiting, chest pain, weakness, blurred vision, mental confusion, sweating, choking, breathing difficulty, and anxiety. These effects began about 10 minutes after drinking and lasted for 1 hour. What drug is likely to cause this presentation?</span></span></span></p>",
    "unique_key": "Q8140329",
    "question_audio": null,
    "question_video": null,
    "map_id": 36464,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Procarbazine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>symptoms</strong> described are consistent with a condition called <strong>disulfiram-like reaction, </strong>which can occur when <strong>alcohol is</strong> <strong>consumed</strong> while taking <strong>certain medication</strong>s. Among the drugs used in<strong> MOPP regimen for Hodgkin&#39;s lymphoma</strong>, the most likely to<strong> cause disulfiram-like reaction with alcohol </strong>is <strong>procarbazine.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Procarbazine </strong>is an<strong> alkylating agent</strong>. It can cause a <strong>disulfiram-like reaction</strong> when <strong>alcohol is consumed, </strong>which can result in symptoms such as<strong> flushing, headache, nausea, vomiting, chest pain, weakness, blurred vision, mental confusion,</strong> s<strong>weating, choking, breathing difficulty, and anxiety</strong>. Patients should be <strong>advised to avoid alcohol</strong> while<strong> taking</strong> <strong>procarbazine to prevent this reaction.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Mechlorethamine:</span></strong><span style=\"font-size:12.0pt\"> Also part of the <strong>MOPP regimen, </strong>mechlorethamine is an <strong>alkylating agent </strong>that causes <strong>DNA crosslinks</strong> but<strong> does not </strong>induce a<strong> disulfiram-like reaction with alcohol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oncovin (Vincristine):</span></strong><span style=\"font-size:12.0pt\"> Vincristine is a <strong>chemotherapeutic agent</strong> that<strong> inhibits microtubule formation</strong>. It <strong>does not</strong> interact with<strong> alcohol </strong>to produce <strong>disulfiram-like reactions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prednisone:</span></strong><span style=\"font-size:12.0pt\"> A<strong> corticosteroid</strong> used in various <strong>chemotherapy regimens,</strong> including<strong> MOPP, prednisone </strong>has many effects on <strong>metabolism and the immune system</strong> but <strong>does not</strong> cause<strong> disulfiram-like reactions </strong>when combined with <strong>alcohol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Procarbazine</strong> can induce a <strong>disulfiram-like reaction</strong> when<strong> taken</strong> with <strong>alcohol,</strong> manifesting as<strong> severe and acute symptoms </strong>shortly after alcohol consumption. It is <strong>crucial for patients</strong> receiving <strong>procarbazine</strong> to <strong>avoid alcohol to prevent</strong> these potentially <strong>distressing</strong> <strong>and dangerous effects. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Drugs causing disulfiram like reaction:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-145325.png\" style=\"height:554px; width:800px\" /></span></strong></span></span></p>",
    "correct_choice_id": 43664,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 10926,
    "choices": [
      {
        "id": 43670,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mitomycin C</span></span></span></p>"
      },
      {
        "id": 43671,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxyurea</span></span></span></p>"
      },
      {
        "id": 43672,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
      },
      {
        "id": 43673,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary fibrosis is an adverse effect of which of the following anti-cancer drugs?</span></span></span></p>",
    "unique_key": "Q6810895",
    "question_audio": null,
    "question_video": null,
    "map_id": 36465,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bleomycin</strong> used in the<strong> treatment of</strong> several types of cancer, including <strong>Hodgkin&#39;s lymphoma, testicular cancer, and ovarian cancer, </strong>is <strong>well-known</strong> for<strong> its potential </strong>to cause<strong> pulmonary fibrosis</strong>.<strong> Pulmonary toxicity </strong>is a<strong> major limiting factor</strong> in its usage.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The mechanism by which <strong>bleomycin causes lung injury</strong> is thought to involve its ability to <strong>induce DNA strand breaks </strong>and <strong>free radical</strong> <strong>formation, leading to inflammation and fibrotic changes in the lungs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Mitomycin C</strong>: This is an <strong>alkylating agent</strong> used in <strong>cancer chemotherapy.</strong> Its common <strong>side effects</strong> include <strong>bone marrow</strong> <strong>suppression, nausea, vomiting, and renal toxicity,</strong> but it is <strong>not</strong> primarily known for <strong>causing pulmonary fibrosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> <strong>Hydroxyurea</strong>: This medication is <strong>used for</strong> various <strong>myeloproliferative disorders</strong> and <strong>sickle cell disease.</strong> Its <strong>side effects </strong>often include <strong>bone marrow suppression and gastrointestinal symptoms,</strong> but it is<strong> not</strong> typically associated with <strong>pulmonary fibrosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Cisplatin</strong>: A <strong>platinum-containing chemotherapy </strong>drug<strong> used to</strong> treat various <strong>types of cancers.</strong> While<strong> nephrotoxicity (kidney</strong> <strong>damage) and ototoxicity (hearing damage)</strong> are common adverse effects, it is <strong>not</strong> typically associated with <strong>pulmonary fibrosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Bleomycin</span></strong><span style=\"font-size:12.0pt\"> is known to cause <strong>pulmonary fibrosis</strong>, which is a condition characterized by the<strong> scarring and thickening of lung tissue.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/05/whatsapp-image-2024-02-05-at-180437_nS2gu6G.jpeg\" style=\"height:702px; width:491px\" /></span></p>",
    "correct_choice_id": 43672,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10928,
    "choices": [
      {
        "id": 43678,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cisplatin</span></span></span></p>"
      },
      {
        "id": 43679,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carboplatin</span></span></span></p>"
      },
      {
        "id": 43680,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxaliplatin</span></span></span></p>"
      },
      {
        "id": 43681,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the platinum compounds</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pharyngolaryngeal dysesthesia is a peculiar side effect of which of the following drugs? </span></span></span></p>",
    "unique_key": "Q9627413",
    "question_audio": null,
    "question_video": null,
    "map_id": 36466,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Oxaliplatin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Oxaliplatin</span></strong><span style=\"font-size:12.0pt\"> is known to cause <strong>pharyngolaryngeal dysesthesia, </strong>which is an <strong>unusual sensory side effect.</strong> Patients can experience<strong> acute</strong> <strong>sensations of cold or burning in the throat and laryngeal area.</strong> This often o<strong>ccurs soon after treatment </strong>and can be<strong> triggered by</strong> <strong>exposure to cold temperatures or the consumption of cold foods and drinks.</strong> While this effect is typically<strong> reversible and resolves</strong> a<strong>fter the drug is discontinued,</strong> it can be <strong>quite distressing for patients during treatmen</strong>t.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cisplatin:</span></strong><span style=\"font-size:12.0pt\"> While Cisplatin is associated with various <strong>side effects,</strong> including <strong>nephrotoxicity and ototoxicity,</strong> <strong>pharyngolaryngeal dysesthesia </strong>is<strong> not</strong> commonly<strong> seen </strong>with this <strong>medication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carboplatin:</span></strong><span style=\"font-size:12.0pt\"> Carboplatin, <strong>another platinum-based chemotherapeutic agent</strong>, tends to have a<strong> different side effect profile</strong>, and<strong> pharyngolaryngeal dysesthesia </strong>is<strong> not</strong> a characteristic <strong>side effect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. All the platinum compounds:</span></strong><span style=\"font-size:12.0pt\"> This option is too broad. While<strong> all platinum compounds </strong>have<strong> side effects r</strong>elated to their <strong>cytotoxicity, pharyngolaryngeal dysesthesia </strong>is specific to <strong>Oxaliplatin </strong>and is <strong>not</strong> generally <strong>seen </strong>with <strong>other platinum-based</strong> <strong>chemotherapeutic agents.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When <strong>patients receiving chemotherapy </strong>with <strong>Oxaliplatin </strong>report <strong>unusual sensations in the throat and laryngeal area</strong>, especially in <strong>response to cold,</strong> it is likely<strong> due to pharyngolaryngeal dysesthesia</strong>. It&#39;s important for<strong> clinicians to be aware of this potential side</strong> <strong>effect </strong>and to<strong> counsel patients </strong>appropriately to<strong> manage symptoms</strong> and<strong> improve their quality of life during treatment.</strong></span></span></span></p>",
    "correct_choice_id": 43680,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10929,
    "choices": [
      {
        "id": 43682,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate</span></span></span></p>"
      },
      {
        "id": 43683,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 Mercaptopurine</span></span></span></p>"
      },
      {
        "id": 43684,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 Thioguanine</span></span></span></p>"
      },
      {
        "id": 43685,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Capacitabine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dose of which of the following drugs should be reduced when prescribed along with allopurinol?&nbsp;</span></span></span></p>",
    "unique_key": "Q8034663",
    "question_audio": null,
    "question_video": null,
    "map_id": 36467,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 6 mercaptopurine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">6-Mercaptopurine (6-MP):</span></strong><span style=\"font-size:12.0pt\"> <strong>Allopurinol</strong> is a<strong> xanthine oxidase inhibitor </strong>used to<strong> decrease the production of uric acid.</strong> Because <strong>xanthine oxidase</strong> is also involved in the<strong> catabolism of 6-MP,</strong> <strong>co-administration with allopurinol</strong> leads to <strong>increased levels of 6-MP.</strong> This can result in <strong>excessive myelosuppression</strong>. Therefore, when<strong> allopurinol is administered concurrently with 6-MP, </strong>the <strong>dose of 6-MP</strong> must be<strong> reduced (commonly to one-third or one-fourth of its standard dose) </strong>to <strong>prevent</strong> potentially <strong>life-threatening toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Methotrexate:</span></strong><span style=\"font-size:12.0pt\"> While methotrexate is <strong>metabolized by the liver</strong> and <strong>excreted by the kidneys, </strong>a<strong>llopurinol</strong> <strong>does not</strong> significantly affect<strong> its plasma levels.</strong> However, <strong>close monitoring</strong> is still warranted due to the<strong> potential for increased toxicity,</strong> but <strong>specific dose reduction </strong>due to<strong> allopurinol</strong> is <strong>not a standard practice.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 6-Thioguanine:</span></strong><span style=\"font-size:12.0pt\"> Like<strong> 6-MP, 6-thioguanine is a purine analog</strong>, and though it has a <strong>similar mechanism of action</strong>, the effect of <strong>allopurinol</strong> on<strong> its metabolism</strong> <strong>does not</strong> usually require a<strong> dose adjustment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Capecitabine:</span></strong><span style=\"font-size:12.0pt\"> Capecitabine, an <strong>oral prodrug</strong> that is<strong> metabolized into 5-fluorouracil,</strong> is <strong>not</strong> primarily <strong>affected</strong> by <strong>allopurinol,</strong> and <strong>dose adjustments</strong> are typically<strong> not </strong>necessary when these<strong> drug</strong>s are<strong> used concurrently.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When <strong>prescribing 6-Mercaptopurine</strong> in<strong> conjunction with allopurinol, </strong>it&#39;s essential to <strong>reduce the dosage of 6-MP to prevent</strong> <strong>increased drug levels </strong>and<strong> potential toxicity </strong>due to the<strong> inhibition of xanthine oxidase by allopurinol. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This<strong> drug interaction</strong> <strong>underscores </strong>the importance of understanding the <strong>metabolic pathways of chemotherapeutic agents</strong> and the <strong>impact of concomitant medications</strong> on these pathways.</span></span></span></p>",
    "correct_choice_id": 43683,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 10930,
    "choices": [
      {
        "id": 43686,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin</span></span></span></p>"
      },
      {
        "id": 43687,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
      },
      {
        "id": 43688,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vinblastine</span></span></span></p>"
      },
      {
        "id": 43689,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dacarbazine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male patient is being treated with ABVD chemotherapy for Hodgkin lymphoma. He presents for cycle 4 of a planned 6 cycles with a new-onset cough. He states it started a week ago and he also feels like he has a little trouble catching his breath. Which drug in the ABVD regimen is the most likely cause of his pulmonary toxicity?</span></span></span></p>",
    "unique_key": "Q3479799",
    "question_audio": null,
    "question_video": null,
    "map_id": 36468,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> ABVD regimen,</strong> used in the treatment of<strong> Hodgkin lymphoma, </strong>includes four drugs: <strong>Doxorubicin, Bleomycin, Vinblastine, </strong>and <strong>Dacarbazine</strong>. Each of these drugs has <strong>its own side effect profile.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the given <strong>patient</strong> who <strong>presents with </strong>a<strong> new-onset cough and shortness of breath,</strong> the drug most likely responsible for these symptoms of <strong>pulmonary toxicity is&nbsp;bleomycin</strong>. The pulmonary toxicity can be manifested as <strong>interstitial pneumonitis and pulmonary</strong> <strong>fibrosis.</strong> Symptoms like<strong> coughing and difficulty breathing</strong> are characteristic of <strong>bleomycin-induced lung damage</strong>. The <strong>risk of</strong> <strong>pulmonary toxicity</strong> <strong>increases </strong>with <strong>higher cumulative doses.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Doxorubicin</strong>: <strong>As part </strong>of the <strong>ABVD regimen,</strong> <strong>doxorubicin&#39;s</strong> primary toxicities are <strong>cardiotoxicity and myelosuppression</strong>. <strong>Pulmonary toxicity</strong> is<strong> not</strong> a common side effect of <strong>doxorubicin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Vinblastine</strong>: <strong>Another component</strong> of the <strong>ABVD regimen</strong>, vinblastine typically causes side effects such as <strong>neurotoxicity and</strong> <strong>myelosuppression. </strong>It is<strong> not </strong>generally associated with<strong> pulmonary toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Dacarbazine</strong>: The<strong> final drug</strong> in the <strong>ABVD regimen</strong>, <strong>dacarbazine</strong> can cause <strong>nausea, vomiting, and myelosuppression,</strong> but like the others, it is<strong> not</strong> known for<strong> causing pulmonary toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In <strong>patients</strong> <strong>undergoing ABVD chemotherapy</strong> who develop <strong>respiratory symptoms </strong>such as <strong>coughing and shortness of breath,</strong> <strong>Bleomycin </strong>is the<strong> agent</strong> within the regimen <strong>most likely</strong> to be <strong>responsible for pulmonary toxicity.</strong></span></span></span></p>",
    "correct_choice_id": 43687,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 10931,
    "choices": [
      {
        "id": 43690,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV hydration, mesna, and frequent urinalyses</span></span></span></p>"
      },
      {
        "id": 43691,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leucovorin and frequent urinalyses</span></span></span></p>"
      },
      {
        "id": 43692,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allopurinol and frequent urinalyses</span></span></span></p>"
      },
      {
        "id": 43693,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV hydration, prophylactic antibiotics, and frequent urinalyses</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 64-year-old male about to undergo therapy for Rhabdomyosarcoma. His chemotherapy includes vincristine, dactinomycin, cyclophosphamide, doxorubicin and ifosfamide. Which of the following is most appropriate to include in chemotherapy orders for this patient? </span></span></span></p>",
    "unique_key": "Q3920056",
    "question_audio": null,
    "question_video": null,
    "map_id": 36469,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) IV hydration, mesna, and frequent urinalyses.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>chemotherapy drugs</strong> listed <strong>(vincristine, dactinomycin, cyclophosphamide, doxorubicin, and ifosfamide)</strong> can be associated with <strong>potential toxicities</strong>, including<strong> damage to the bladder and kidneys</strong>. Therefore, it is important to include <strong>measures to protect </strong>these <strong>organs </strong>during<strong> treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>IV hydration, mesna, and frequent urinalyses,</strong> which are <strong>commonly used to protect the bladder and kidneys</strong> during <strong>chemotherapy</strong> with <strong>ifosfamide and cyclophosphamide. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>IV hydration</strong> can help <strong>flush out</strong> the drugs and prevent the<strong> buildup of toxic metabolites </strong>in the <strong>kidneys. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Mesna</strong> can <strong>prevent damage to the bladder lining </strong>by <strong>neutralizing metabolites of ifosfamide. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Frequent urinalyses</strong> can<strong> help</strong> <strong>monitor </strong>for <strong>signs of kidney or bladder toxicity.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Leucovorin and frequent urinalyses. </span></strong><span style=\"font-size:12.0pt\"><strong>Leucovorin</strong> is used in <strong>combination with the methotrexate,</strong> which is<strong> not </strong>included in the <strong>listed chemotherapy drugs. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Allopurinol and frequent urinalyses</span></strong><span style=\"font-size:12.0pt\">. <strong>Allopurinol </strong>is used to<strong> prevent uric acid buildup </strong>during <strong>chemotherapy for lymphoma</strong> but is<strong> not</strong> used for <strong>rhabdomyosarcoma. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IV hydration, prophylactic antibiotics, and frequent urinalyses</span></strong><span style=\"font-size:12.0pt\">. <strong>Prophylactic antibiotics </strong>may be used to <strong>prevent infections</strong> <strong>during chemotherapy</strong>, but is <strong>not</strong> typically <strong>required for rhabdomyosarcoma chemotherapy. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For<strong> patients receiving chemotherapy regimens</strong> that include <strong>cyclophosphamide and ifosfamide,</strong> it is crucial to <strong>implement measures</strong> to<strong> prevent bladder toxicity. </strong>This includes the <strong>use of IV hydration to facilitate dilution of urine, mesna to chemically neutralize toxic</strong> <strong>metabolites,</strong> and <strong>regular monitoring of urinary function</strong> through<strong> frequent urinalyses</strong>. These <strong>steps </strong>are<strong> essential to protect </strong>the <strong>patient&rsquo;s urinary tract </strong>and ensure the<strong> safe administration of potentially nephrotoxic chemotherapy agents.</strong></span></span></span></p>",
    "correct_choice_id": 43690,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 10932,
    "choices": [
      {
        "id": 43694,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">G1 phase</span></span></span></p>"
      },
      {
        "id": 43695,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S phase</span></span></span></p>"
      },
      {
        "id": 43696,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">G2 phase</span></span></span></p>"
      },
      {
        "id": 43697,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">M phase</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vinblastine inhibits which phase of cell cycle? </span></span></span></p>",
    "unique_key": "Q8041542",
    "question_audio": null,
    "question_video": null,
    "map_id": 36470,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) M phase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Vinblastine</span></strong><span style=\"font-size:12.0pt\"> is a <strong>chemotherapeutic agent</strong> classified under the<strong> vinca alkaloids,</strong> which are known for their<strong> ability to inhibit microtubule</strong> <strong>formation.</strong> This action<strong> disrupts the mitotic spindle formation</strong> necessary for <strong>chromosome separation</strong> during the <strong>M</strong> <strong>phase (mitosis) of the cell cycle</strong>. Therefore, <strong>vinblastine effectively halts</strong> the <strong>cell cycle in the M phase, preventing cells</strong> <strong>from properly</strong> <strong>completing mitosis</strong>,<strong> leading to cell death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. G1 phase:</span></strong><span style=\"font-size:12.0pt\"> This phase involves the<strong> preparation of the cell to enter the S phase </strong>but is<strong> not </strong>affected by <strong>vinblastine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. S phase:</span></strong><span style=\"font-size:12.0pt\"> The phase where <strong>DNA replication occurs</strong>; <strong>vinblastine does not</strong> directly affect <strong>DNA synthesis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. G2 phase:</span></strong><span style=\"font-size:12.0pt\"> The phase where the <strong>cell prepares for mitosis</strong>; although important for <strong>cell cycle progression,</strong> <strong>vinblastine</strong> specifically<strong> targets and disrupts</strong> the<strong> mitotic phase rather </strong>than <strong>this preparatory phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-153051.png\" style=\"height:408px; width:1000px\" /></span></u></strong></span></span></p>",
    "correct_choice_id": 43697,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10934,
    "choices": [
      {
        "id": 43702,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Actinomycin D </span></span></span></p>"
      },
      {
        "id": 43703,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asparaginase</span></span></span></p>"
      },
      {
        "id": 43704,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mitomycin </span></span></span></p>"
      },
      {
        "id": 43705,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6-mercaptopurine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is an inhibitor of DNA replication? </span></span></span></p>",
    "unique_key": "Q7537451",
    "question_audio": null,
    "question_video": null,
    "map_id": 36472,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) 6-mercaptopurine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">6-mercaptopurine (6-MP):</span></strong><span style=\"font-size:12.0pt\"> This drug is a <strong>purine antimetabolite</strong> that<strong> interferes with DNA replication.</strong> It is<strong> incorporated</strong> into <strong>DNA</strong> <strong>during synthesis</strong>, leading to <strong>faulty DNA and inhibition of replication.</strong> <strong>6-MP</strong> is particularly used in the treatment of<strong> leukemia because</strong> the<strong> malignant cells </strong>have a <strong>high turnover rate</strong> and are<strong> more likely to incorporate</strong> these <strong>false building blocks</strong> into <strong>their DNA.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Actinomycin D:</span></strong><span style=\"font-size:12.0pt\"> This drug <strong>binds </strong>to <strong>DNA and inhibits RNA polymerase, </strong>which is responsible for <strong>transcribing RNA from the</strong> <strong>DNA template.</strong> While it does <strong>affect genetic material,</strong> it is <strong>not</strong> a <strong>direct inhibitor of DNA replication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Asparaginase:</span></strong><span style=\"font-size:12.0pt\"><strong> Works</strong> by <strong>breaking down</strong> the <strong>amino acid asparagine</strong>, which is necessary for<strong> protein synthesis in tumor cells.</strong> It <strong>does no</strong>t directly <strong>inhibit DNA replication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mitomycin:</span></strong><span style=\"font-size:12.0pt\"> Acts as an <strong>alkylating agent</strong>, forming <strong>cross-links</strong> within the <strong>DNA strands</strong>. Although this <strong>affects DNA structure</strong> and<strong> function</strong>, it <strong>does not</strong> <strong>inhibit</strong> the<strong> replication process directly like 6-MP does.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>6-mercaptopurine</strong> is a <strong>crucial medication</strong> in the treatment of certain types of<strong> leukemia,</strong> where it <strong>serves as an inhibitor of DNA</strong> <strong>replication </strong>by<strong> mimicking purine nucleotides.</strong> This specific action <strong>disrupts the synthesis of DNA</strong>, which is <strong>critical for the proliferation</strong> of<strong> cancer cells. </strong></span></span></span></p>",
    "correct_choice_id": 43705,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10935,
    "choices": [
      {
        "id": 43706,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Etoposide </span></span></span></p>"
      },
      {
        "id": 43707,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
      },
      {
        "id": 43708,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paclitaxel </span></span></span></p>"
      },
      {
        "id": 43709,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vincristine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neurotoxicity is dose-limiting for which of the following drugs? </span></span></span></p>",
    "unique_key": "Q5939436",
    "question_audio": null,
    "question_video": null,
    "map_id": 36473,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Vincristine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vincristine</strong> can <strong>damage</strong> <strong>peripheral nerves,</strong> leading to a range of <strong>neurological symptoms</strong> such as <strong>numbness, tingling, weakness, and</strong> <strong>difficulty walking</strong>. The<strong> severity of neurotoxicity </strong>is directly related to the <strong>dose of the drug</strong>, and it is a <strong>dose-limiting toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Etoposide:</span></strong><span style=\"font-size:12.0pt\"> Etoposide can cause<strong> myelosuppression</strong>, leading to<strong> low blood cell counts,</strong> which is generally the<strong> dose-limiting</strong> <strong>toxicity </strong>for this drug.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methotrexate:</span></strong><span style=\"font-size:12.0pt\"> While methotrexate can cause various<strong> side effects</strong> including<strong> mucositis and hepatotoxicity,</strong> its <strong>dose-limiting</strong> <strong>toxicity </strong>is often <strong>myelosuppression.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Paclitaxel:</span></strong><span style=\"font-size:12.0pt\"> Paclitaxel can cause <strong>myelosuppression and neuropathy</strong>, but the <strong>primary dose-limiting toxicity </strong>is typically <strong>bone</strong> <strong>marrow suppression.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vincristine&#39;s dose-limiting toxicity</strong> is<strong> neurotoxicity,</strong> which necessitates careful <strong>monitoring of neurological symptoms</strong> and <strong>adjustment</strong> of <strong>dosing </strong>to<strong> prevent severe peripheral neuropathy. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Myelosuppression </strong>is <strong>dose limiting </strong>for<strong> paclitaxel, etoposide, and methotrexate.</strong></span></span></span></p>",
    "correct_choice_id": 43709,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10937,
    "choices": [
      {
        "id": 43714,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of Dihydrofolate reductase </span></span></span></p>"
      },
      {
        "id": 43715,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of N5 tetrahydro folate reductase </span></span></span></p>"
      },
      {
        "id": 43716,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of tyrosine kinase</span></span></span></p>"
      },
      {
        "id": 43717,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of purine metabolism</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 20-year-old boy presented with slow growing mass on the medial side of thigh. Investigations revealed it to be osteosarcoma and patient was started on methotrexate. Mechanism of action of methotrexate as an anticancer drug is:</span></span></span></p>",
    "unique_key": "Q6098509",
    "question_audio": null,
    "question_video": null,
    "map_id": 36474,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Inhibition of Dihydrofolate reductase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methotrexate</strong> is an <strong>antimetabolite</strong> that interferes with the<strong> synthesis of nucleic acids </strong>in <strong>rapidly dividing cells</strong> such as <strong>cancer cells.</strong> It <strong>inhibits the activity of DHFR</strong>, which is an enzyme that is necessary for the <strong>synthesis of tetrahydrofolate, </strong>a <strong>coenzyme</strong> that is involved in the <strong>synthesis of nucleotides</strong>. By<strong> inhibiting DHFR, methotrexate reduces the availability of tetrahydrofolate,</strong> which in turn<strong> inhibits</strong> the<strong> synthesis of nucleotides</strong>, ultimately leading to <strong>decreased DNA synthesis and cell division.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhibition of N5 tetrahydro folate reductase:</span></strong><span style=\"font-size:12.0pt\"> This option is<strong> incorrect </strong>because there is<strong> no enzyme</strong> named <strong>N5 tetrahydro</strong> <strong>folate reductase</strong> that<strong> methotrexate</strong> is known to <strong>inhibit.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibition of tyrosine kinase:</span></strong><span style=\"font-size:12.0pt\"> This is the <strong>action of </strong>drugs like <strong>imatinib,</strong> <strong>not methotrexate. Tyrosine kinase inhibitors</strong> are <strong>used</strong> in the treatment of certain <strong>types of leukemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhibition of purine metabolism:</span></strong><span style=\"font-size:12.0pt\"> While <strong>methotrexate</strong> can <strong>impact purine metabolism indirectly </strong>by <strong>its action</strong> on <strong>DHFR</strong>, the <strong>direct inhibition of purine metabolism </strong>is characteristic of drugs like <strong>6-mercaptopurine, not methotrexate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The key <strong>mechanism of action</strong> of<strong> methotrexate</strong> in the treatment of <strong>cancer</strong>, including <strong>osteosarcoma,</strong> is the<strong> inhibition of dihydrofolate</strong> <strong>reductase.</strong> This action results in <strong>decreased nucleotide biosynthesis</strong>, which is<strong> vital for DNA replication </strong>and <strong>cell division in rapidly</strong> <strong>dividing cancer cells. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding this <strong>mechanism</strong> is critical when <strong>using methotrexate</strong> as an <strong>anticancer agent</strong>, as it informs<strong> both its therapeutic effects</strong> <strong>and its toxicity profile.</strong></span></span></span></p>",
    "correct_choice_id": 43714,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 10896,
    "choices": [
      {
        "id": 43550,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Used in non-small cell carcinoma of lung</span></span></span></p>"
      },
      {
        "id": 43551,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a small molecule tyrosine kinase inhibitor acting as EGFR antagonist</span></span></span></p>"
      },
      {
        "id": 43552,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Food decreases absorption</span></span></span></p>"
      },
      {
        "id": 43553,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It causes skin rashes and diarrhoea</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All are true about Erlotinib except?</span></span></span></p>",
    "unique_key": "Q6236379",
    "question_audio": null,
    "question_video": null,
    "map_id": 36479,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Food decreases absorption</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Erlotinib</strong> is a <strong>drug</strong> used primarily in the treatment of <strong>non-small cell lung carcinoma and pancreatic carcinoma, </strong>specifically when <strong>combined</strong> with<strong> gemcitabine</strong>. It functions as a <strong>tyrosine kinase inhibitor </strong>targeting the<strong> epidermal growth factor receptor (EGFR)</strong>, which is significant in the <strong>pathogenesis of various cancers.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contrary to the statement in <strong>option C, food </strong>actually<strong> increases the absorption of Erlotinib,</strong> not decreases it. Studies indicate that the presence of<strong> food can increase the absorption of Erlotinib </strong>by approximately <strong>100%,</strong> suggesting that how <strong>Erlotinib </strong>is <strong>administered</strong> in <strong>relation to meals </strong>can significantly affect <strong>its efficacy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Used in non-small cell carcinoma of lung:</span></strong><span style=\"font-size:12.0pt\"> This statement is<strong> correct.</strong> Erlotinib is indeed used for treating<strong> non-small cell lung carcinoma</strong>, acting primarily by <strong>inhibiting the EGFR pathways</strong> involved in <strong>cancer cell proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. It is a small molecule tyrosine kinase inhibitor acting as EGFR antagonist:</span></strong><span style=\"font-size:12.0pt\"> This is also<strong> true</strong>. Erlotinib<strong> inhibits</strong> the <strong>activity of</strong> the<strong> EGFR</strong>, which is a <strong>tyrosine kinase, </strong>thereby interfering with the<strong> growth and survival of cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It causes skin rashes and diarrhoea:</span></strong><span style=\"font-size:12.0pt\"> Accurate as well. The most<strong> common adverse effects</strong> associated with <strong>Erlotinib</strong> include an <strong>acneiform skin rash and diarrhea</strong>, along with <strong>other side effects</strong> like<strong> anorexia and fatigue.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Erlotinib </strong>is a <strong>tyrosine kinase inhibitor</strong> used notably for<strong> non-small cell lung carcinoma and pancreatic carcinoma</strong>. Additionally, the <strong>absorption of Erlotinib </strong>is<strong> increased by food, </strong>which is an important consideration for its clinical use.</span></span></span></p>",
    "correct_choice_id": 43552,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10901,
    "choices": [
      {
        "id": 43570,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral neuropathy</span></span></span></p>"
      },
      {
        "id": 43571,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diarrhea</span></span></span></p>"
      },
      {
        "id": 43572,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Teratogenicity</span></span></span></p>"
      },
      {
        "id": 43573,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Deep vein thrombosis</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thalidomide was once used for treating the emesis of pregnancy. Later, it was withdrawn from the market due to its side effects. However, it was reintroduced for certain indications like multiple myelomA. Which of the following is not a side effect of thalidomide?</span></span></span></p>",
    "unique_key": "Q8084760",
    "question_audio": null,
    "question_video": null,
    "map_id": 36480,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Diarrhea</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thalidomide</strong> is <strong>notorious </strong>for its<strong> initial use</strong> during<strong> pregnancy </strong>to <strong>treat nausea and vomiting</strong>, but it was <strong>rapidly withdrawn</strong> due to <strong>severe teratogenic effects</strong> that resulted in <strong>substantial birth defects</strong>. It has since been <strong>reintroduced, </strong>especially for the<strong> treatment of</strong> <strong>diseases</strong> such as <strong>multiple myeloma </strong>due to its<strong> immunomodulatory effects. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thalidomide</strong> is <strong>known to cause constipation</strong> rather than diarrhea, which aligns with its common gastrointestinal side effects, contrasting with the<strong> incorrect option</strong> that suggests it<strong> causes diarrhea. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Other</strong> notable<strong> adverse effects of thalidomide</strong> include <strong>peripheral neuropathy,</strong> where patients experience <strong>sensory changes</strong> like <strong>numbness or tingling in the extremities</strong>. Its<strong> teratogenic</strong> potential is<strong> highly</strong> significant, <strong>leading to severe limb </strong>and <strong>organ deformities</strong> when taken<strong> during pregnancy</strong>. Additionally,<strong> thalidomide increases </strong>the <strong>risk of thromboembolic </strong>events such as <strong>deep vein thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Peripheral neuropathy:</span></strong><span style=\"font-size:12.0pt\"> Accurately listed as a <strong>side effect</strong>, it involves<strong> nerve damage </strong>resulting in<strong> pain, numbness, or tingling</strong> <strong>sensations, </strong>primarily in the<strong> hands and feet.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Teratogenicity:</span></strong><span style=\"font-size:12.0pt\"> <strong>Correctly</strong> identified as a <strong>side effect</strong>, <strong>thalidomide</strong> causes <strong>severe birth defects,</strong> a major reason for its <strong>initial</strong> <strong>market withdrawal.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Deep vein thrombosis:</span></strong><span style=\"font-size:12.0pt\"> This is a<strong> valid side effect</strong>, with thalidomide <strong>increasing the risk for blood clots,</strong> necessitating <strong>caution and preventive </strong>measures in </span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>its administration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Major adverse effects of thalidomide:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Teratogenicity:</strong> <strong>Thalidomide</strong> is associated with<strong> severe birth defects</strong>, particularly <strong>limb abnormalities,</strong> when taken <strong>during</strong> <strong>pregnancy.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Peripheral neuropathy</strong>: Thalidomide can cause <strong>nerve damage</strong> that results in <strong>tingling, numbness, or pain </strong>in the <strong>hands</strong> <strong>and feet.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thromboembolism</strong>: Thalidomide use is associated with an <strong>increased risk of blood clots,</strong> including <strong>deep vein thrombosis</strong> and<strong> pulmonary embolism.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Somnolence</strong>: Thalidomide can cause <strong>drowsiness or sedation</strong>, which may<strong> impair the ability </strong>to <strong>perform tasks</strong> that require <strong>alertness.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bradycardia:</strong> Thalidomide may <strong>cause a slow heart rate</strong>, which can lead to <strong>dizziness or fainting.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Constipation</strong>: Thalidomide can cause <strong>gastrointestinal symptoms such as constipation, nausea, and vomiting.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Hypersensitivity reactions</strong>: Thalidomide can cause<strong> allergic reactions</strong>, including <strong>rash, itching, and difficulty breathing.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 43571,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10916,
    "choices": [
      {
        "id": 43630,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Erlotinib</span></span></span></p>"
      },
      {
        "id": 43631,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ribociclib </span></span></span></p>"
      },
      {
        "id": 43632,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dabrafenib </span></span></span></p>"
      },
      {
        "id": 43633,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nilotinib</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following anticancer drugs act at the target shown in figure? </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/407.jpg\" style=\"height:226px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q1287108",
    "question_audio": null,
    "question_video": null,
    "map_id": 36476,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Ribociclib</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ribociclib</strong> is a <strong>selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6),</strong> which are <strong>enzymes </strong>that play a critical <strong>role in cell cycle progression. </strong>These <strong>kinases</strong> <strong>promote cell proliferation by phosphorylating</strong> and <strong>inactivating</strong> the <strong>retinoblastoma protein (Rb), </strong>which in turn allows the <strong>cell to pass </strong>through the<strong> G1 checkpoint</strong> and <strong>enter S phase</strong> of the <strong>cell cycle.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Inhibition of CDK4/6 </strong>by <strong>Ribociclib</strong> results in<strong> cell cycle arrest in the G1 phase</strong>, leading to <strong>inhibition of cell proliferation.</strong> This <strong>mechanism of action </strong>is particularly<strong> relevant in cancer cells</strong>, which often have <strong>aberrant regulation of the cell cycle and increased reliance on CDK4/6 activity to drive proliferation.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ribociclib</strong> is approved for <strong>use in combination</strong> with other therapies for the treatment of<strong> estrogen receptor-positive</strong>, <strong>human epidermal growth factor receptor 2-negative (HR+/HER2-)</strong> <strong>advanced </strong>or <strong>metastatic breast cancer. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>Erlotinib</strong>: <strong>Erlotinib </strong>is a <strong>tyrosine kinase inhibitor</strong> that <strong>targets the epidermal growth factor receptor (EGFR) pathway</strong>. It works by <strong>blocking the activity of the EGFR protein, </strong>which is often <strong>overexpressed </strong>in certain types of <strong>cancer cells</strong> and contributes to <strong>tumor growth and spread</strong>. <strong>Erlotinib </strong>is primarily <strong>used </strong>to treat<strong> non-small cell lung cancer and pancreatic cancer. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Dabrafenib</strong>:<strong> Dabrafenib </strong>is a<strong> selective inhibitor of the BRAF protein</strong>, which is a key component of the<strong> MAP kinase signalling</strong> <strong>pathway</strong>. This pathway is<strong> frequently mutated in certain types of cancer</strong>, including<strong> melanoma, and drives tumor growth</strong> <strong>and survival</strong>. Dabrafenib is<strong> used to treat advanced melanoma</strong> with<strong> BRAF V600E or V600K mutations</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Nilotinib</strong>: Nilotinib is a<strong> tyrosine kinase inhibitor</strong> that targets the <strong>BCR-ABL protein,</strong> which is a <strong>fusion protein</strong> that drives the <strong>growth of chronic myelogenous leukemia (CML) cells. </strong>It works by<strong> blocking the activity</strong> of the<strong> BCR-ABL protein</strong>, leading to <strong>inhibition</strong> of <strong>cell proliferation and induction of cell death</strong>. <strong>Nilotinib </strong>is taken <strong>orally</strong> and is primarily used to treat<strong> CML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ribociclib </strong>is a<strong> targeted anticancer</strong> therapy that <strong>inhibits CDK4/6</strong>, key enzymes in <strong>cell cycle regulation</strong>. It is <strong>used to </strong>halt the <strong>progression of certain cancers</strong> by<strong> inducing cell cycle arrest at the G1 phase,</strong> thereby <strong>impeding the cancer cells</strong> <strong>from multiplying.</strong></span></span></span></p>",
    "correct_choice_id": 43631,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 10918,
    "choices": [
      {
        "id": 43638,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mTOR inhibitor</span></span></span></p>"
      },
      {
        "id": 43639,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proteasome inhibitor</span></span></span></p>"
      },
      {
        "id": 43640,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Histone deacetylase inhibitors</span></span></span></p>"
      },
      {
        "id": 43641,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Protein tyrosine kinase inhibitor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bortezomib is a drug used for treatment of multiple myeloma. What is the mechanism of action of this drug?</span></span></p>",
    "unique_key": "Q3428289",
    "question_audio": null,
    "question_video": null,
    "map_id": 36477,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Proteasome inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bortezomib</strong> is used to treat <strong>multiple myeloma.</strong> It works by<strong> inhibiting the activity of the proteasome,</strong> a <strong>large protein</strong> <strong>complex</strong> that is responsible for the<strong> degradation of many cellular proteins. </strong>Specifically,<strong> Bortezomib </strong>targets the<strong> 26S</strong> <strong>proteasome, </strong>which is involved in the<strong> degradation of ubiquitinated proteins.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">By<strong> inhibiting proteasome activity, Bortezomib</strong> interferes with the<strong> normal process of protein degradation</strong> and leads to the <strong>accumulation of misfolded or damaged proteins within the cell.</strong> This can cause<strong> cell cycle arrest, activation of</strong> <strong>apoptotic pathways,</strong> and ultimately, <strong>cell death.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"><strong> mTOR inhibitor</strong>: The <strong>mammalian target of rapamycin (mTOR)</strong> is a <strong>protein kinase</strong> that plays a key role in <strong>regulating cell</strong> <strong>growth and proliferation.</strong> <strong>Inhibition of mTOR activity </strong>can <strong>slow down</strong> or <strong>stop the growth of cancer cells.</strong> <strong>mTOR inhibitors</strong> such as <strong>temsirolimus and everolimus</strong> are used to <strong>treat renal cell carcinoma </strong>and <strong>breast cancer. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Histone deacetylase inhibitors</strong>: HDAC enzymes are involved in the <strong>regulation of gene expression</strong>. By <strong>altering</strong> the <strong>acetylation status of histone proteins</strong>, <strong>HDAC inhibitors</strong> can induce changes in <strong>gene expression</strong> that can lead to <strong>cell cycle arrest,</strong> <strong>differentiation, or apoptosis.</strong> These drugs are<strong> used </strong>to treat various types of <strong>cancer, </strong>including<strong> lymphoma and leukaemia.</strong> Examples of <strong>HDAC inhibitors </strong>include<strong> vorinostat, romidepsin, and belinostat. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Protein tyrosine kinase inhibitor</strong>:<strong> Protein tyrosine kinases (PTKs)</strong> are enzymes that play a role in<strong> cell signaling pathways</strong> and are often <strong>overexpressed or mutated in cancer cells</strong>. <strong>PTK inhibitors</strong> such as<strong> imatinib, dasatinib, and erlotinib</strong> <strong>target specific</strong> <strong>tyrosine kinases </strong>and <strong>inhibit their activity, </strong>leading to<strong> decreased cell proliferation and survival</strong>. These drugs are <strong>used to treat </strong>various <strong>types of cancer,</strong> including <strong>chronic myelogenous leukemia (CML) </strong>and some forms of<strong> lung cancer.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bortezomib&#39;s </strong>role as a <strong>proteasome inhibitor</strong> makes it an<strong> effective drug </strong>in the treatment of <strong>multiple myeloma,</strong> by <strong>disrupting</strong> the <strong>regulated degradation of proteins</strong> and causing a <strong>build-up that is toxic to cancer cells.</strong></span></span></span></p>",
    "correct_choice_id": 43639,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10927,
    "choices": [
      {
        "id": 43674,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Erlotinib</span></span></span></p>"
      },
      {
        "id": 43675,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Regorafenib</span></span></span></p>"
      },
      {
        "id": 43676,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sorafenib</span></span></span></p>"
      },
      {
        "id": 43677,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vemurafenib</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following Tyrosine kinase inhibitors is used for the treatment of malignant melanoma? </span></span></span></p>",
    "unique_key": "Q9951085",
    "question_audio": null,
    "question_video": null,
    "map_id": 36478,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Vemurafenib</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Vemurafenib</span></strong><span style=\"font-size:12.0pt\"> is a <strong>tyrosine kinase inhibitor</strong> that specifically targets the<strong> BRAF V600E mutation</strong> in <strong>malignant melanoma.</strong> This mutation is <strong>present</strong> in a <strong>significant percentage of melanomas</strong> and contributes to the<strong> growth of cancer cells.</strong> By <strong>inhibiting the mutated BRAF</strong> <strong>kinase, vemurafenib</strong> can<strong> slow or stop </strong>the <strong>growth of the melanoma cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Erlotinib:</span></strong><span style=\"font-size:12.0pt\"> Erlotinib is used primarily for <strong>non-small cell lung carcinoma (NSCLC)</strong> and <strong>pancreatic cancer.</strong> It <strong>targets </strong>the <strong>epidermal growth factor receptor (EGFR),</strong> which is<strong> overexpressed or mutated </strong>in these cancers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Regorafenib:</span></strong><span style=\"font-size:12.0pt\"> Regorafenib is used for <strong>colorectal carcinoma and gastrointestinal stromal tumors (GIST).</strong> It <strong>inhibits</strong> multiple <strong>protein kinases</strong> involved in<strong> tumor angiogenesis, oncogenesis, </strong>and the<strong> tumor microenvironment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sorafenib:</span></strong><span style=\"font-size:12.0pt\"> Sorafenib is used mainly for<strong> hepatocellular carcinoma (HCC) </strong>and also for<strong> renal cell carcinoma (RCC)</strong>. It <strong>targets</strong> <strong>multiple kinases</strong>, including those involved in <strong>angiogenesis and cell proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vemurafenib</strong> is<strong> used for </strong>the treatment of <strong>malignant melanoma.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Erlotinib </strong>is <strong>used for&nbsp; non-small cell carcinoma of lung and pancreatic carcinoma.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Regorafenib</strong> is used for<strong> colorectal carcinoma and GIST.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Sorafenib </strong>is used for <strong>hepatocellular carcinoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Indications of tyrosine kinase inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-151648.png\" style=\"height:543px; width:900px\" /></span></strong></span></span></p>",
    "correct_choice_id": 43677,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10909,
    "choices": [
      {
        "id": 43602,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab directly inhibits the proliferation of T-cells</span></span></span></p>"
      },
      {
        "id": 43603,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab promotes the activation of B-cells</span></span></span></p>"
      },
      {
        "id": 43604,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab blocks the binding of interleukin-2 (IL-2) to its receptor on activated T-cells</span></span></span></p>"
      },
      {
        "id": 43605,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab enhances the differentiation of dendritic cells</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements best describes the mechanism of action of basiliximab?</span></span></span></p>",
    "unique_key": "Q6966459",
    "question_audio": null,
    "question_video": null,
    "map_id": 36493,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Basiliximab blocks the binding of interleukin-2 (IL-2) to its receptor on activated T-cells</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Basiliximab</strong> is a<strong> chimeric (human-murine) monoclonal antibody </strong>that targets the<strong> IL-2 receptor alpha chain </strong>(also known as <strong>CD25</strong>) on the <strong>surface of activated T-cells.</strong> By <strong>binding </strong>to<strong> this receptor</strong>,<strong> basiliximab</strong> effectively<strong> prevents interleukin-2 (IL-2)</strong> from <strong>interacting with</strong> its receptor.<strong> IL-2</strong> is a crucial <strong>growth factor for T-cells, </strong>particularly following <strong>antigen exposure</strong>. Without the<strong> ability to bind to its</strong> <strong>receptor, IL-2 cannot signal the T-cell to proliferate and activate</strong>, which is essential in the <strong>immune response</strong>, especially concerning the <strong>rejection of transplanted organs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Basiliximab directly inhibits the proliferation of T-cells:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect.</strong> because <strong>basiliximab </strong>itself <strong>does not </strong>directly<strong> inhibit cell</strong> <strong>proliferation;</strong> instead, it<strong> prevents IL-2</strong> from <strong>activating T-cells, </strong>which<strong> indirectly inhibits their proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Basiliximab promotes the activation of B-cells:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect. Basiliximab&rsquo;s</strong> action is specific to <strong>T-cells </strong>and <strong>does not</strong> involve <strong>direct effects on B-cell activation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Basiliximab enhances the differentiation of dendritic cells:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong>. Basiliximab&#39;s mechanism of action is <strong>centered on T-cells </strong>and <strong>does not </strong>affect the <strong>differentiation of dendritic cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Basiliximab</strong> serves as an<strong> immunosuppressant </strong>by specifically <strong>blocking the IL-2 receptor on activated T-cells</strong>, thereby <strong>preventing</strong> their <strong>activation and proliferation. </strong>This selective<strong> inhibition</strong> is critical in <strong>preventing organ rejection </strong>following <strong>transplantation,</strong> making <strong>basiliximab</strong> a<strong> valuable therapeutic</strong> tool in<strong> transplant medicine.</strong></span></span></span></p>",
    "correct_choice_id": 43604,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10905,
    "choices": [
      {
        "id": 43586,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tofacitinib inhibits Janus kinase (JAK) enzymes</span></span></span></p>"
      },
      {
        "id": 43587,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) receptor</span></span></span></p>"
      },
      {
        "id": 43588,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tocilizumab is approved for the treatment of rheumatoid arthritis</span></span></span></p>"
      },
      {
        "id": 43589,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tofacitinib is administered by intravenous route</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is false about tofacitinib and tocilizumab?</span></span></span></p>",
    "unique_key": "Q7189761",
    "question_audio": null,
    "question_video": null,
    "map_id": 36490,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tofacitinib is administered by intravenous route</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This statement is <strong>false</strong>. <strong>Tofacitinib</strong> is <strong>not</strong> administered <strong>intravenously</strong>; it is an <strong>orally administered </strong>medication. This <strong>distinguishes it</strong> <strong>from</strong> many <strong>other biologic drugs </strong>used in the treatment of conditions like <strong>rheumatoid arthritis</strong>, which are often <strong>administered via injection or infusion.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tofacitinib inhibits Janus kinase (JAK) enzymes.</span></strong><span style=\"font-size:12.0pt\"><strong> True.</strong> <strong>Tofacitinib functions </strong>as a <strong>Janus kinase inhibitor,</strong> <strong>targeting</strong> and <strong>inhibiting these enzymes</strong>, which are <strong>crucial in the signaling pathways</strong> for various<strong> inflammatory processes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) receptor - </span></strong><span style=\"font-size:12.0pt\"><strong>True.</strong> <strong>Tocilizumab </strong>is a<strong> monoclonal antibody</strong> that <strong>specifically binds</strong> to and <strong>inhibits the IL-6 receptor,</strong> thereby impacting the <strong>action of interleukin-6, </strong>a <strong>cytokine</strong> involved in <strong>inflammation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tocilizumab is approved for the treatment of rheumatoid arthritis - </span></strong><span style=\"font-size:12.0pt\">&nbsp;<strong>True. Tocilizumab </strong>has been <strong>approved for</strong> the treatment of<strong> rheumatoid arthritis</strong>, particularly for patients who <strong>have not </strong>responded <strong>adequately to other treatments.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-122248.png\" style=\"height:434px; width:1000px\" /></span></u></strong></span></span></p>",
    "correct_choice_id": 43589,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10908,
    "choices": [
      {
        "id": 43598,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azathioprine is used as immunosuppressant drug</span></span></span></p>"
      },
      {
        "id": 43599,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Some of these drugs are activated by hypoxanthine guanine phosphoribosyl transferase (HGPRTase)</span></span></span></p>"
      },
      {
        "id": 43600,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fludarabine is the drug of choice for CLL.</span></span></span></p>"
      },
      {
        "id": 43601,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cladribine is degraded by adenosine deaminase</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 52-year-old male with a history of chronic lymphocytic leukemia (CLL) is seen in the oncology clinic for a routine follow-up. His treatment regimen includes a purine analog, and his latest lab tests show a good response to the therapy.&nbsp;Which of the following statements is NOT true about purine analogs?</span></span></span></p>",
    "unique_key": "Q1775454",
    "question_audio": null,
    "question_video": null,
    "map_id": 36492,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Cladribine is degraded by adenosine deaminase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This statement is <strong>false</strong>. <strong>Cladribine </strong>is actually<strong> resistant to degradation by adenosine deaminase,</strong> which makes it an <strong>effective agent</strong> in treating cancers like<strong> hairy cell leukemia.</strong> Its<strong> resistance</strong> allows it to <strong>remain active longer</strong> and<strong> exert sustained effects </strong>against <strong>cancer</strong> <strong>cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Purine analogs</strong> are a critical class of drugs used in the <strong>treatment of</strong> <strong>various leukemias,</strong> including<strong> CLL.</strong> They function by <strong>mimicking</strong> <strong>natural purines,</strong> integrating into <strong>DNA strands</strong>, and<strong> disrupting DNA synthesis</strong>, which is crucial for the <strong>proliferation of cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Azathioprine is used as an immunosuppressant drug:</span></strong><span style=\"font-size:12.0pt\"> <strong>True.</strong> Azathioprine <strong>inhibits DNA synthesis</strong>, effectively <strong>suppressing</strong> the<strong> immune response</strong>, which i<strong>s beneficial</strong> in conditions like <strong>autoimmune diseases </strong>and in <strong>preventing organ transplant rejection.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Some of these drugs are activated by hypoxanthine guanine phosphoribosyl transferase (HGPRTase):</span></strong><span style=\"font-size:12.0pt\"> <strong>True.</strong> Drugs like <strong>mercaptopurine and thioguanine</strong> need activation by<strong> HGPRTase</strong> to exert their <strong>cytotoxic effects,</strong> making them <strong>effective</strong> in certain <strong>types of leukemia</strong> where this<strong> enzyme is active.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fludarabine is the drug of choice for CLL:</span></strong><span style=\"font-size:12.0pt\"><strong> True.</strong> <strong>Fludarabine</strong> is commonly <strong>used and highly effective</strong> in the treatment of <strong>CLL</strong> due to its<strong> potent ability </strong>to <strong>interfere with DNA replication </strong>in the<strong> rapidly dividing leukemic cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cladribine&#39;s resistance</strong> to <strong>adenosine deaminase </strong>makes it a particularly <strong>potent choice in certain leukemias</strong>, contrary to the<strong> incorrect</strong> claim of <strong>its degradation by this enzyme.</strong></span></span></span></p>",
    "correct_choice_id": 43601,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 10921,
    "choices": [
      {
        "id": 43650,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It is a macrolide lactone</span></p>"
      },
      {
        "id": 43651,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It inhibits the gene transcription of interleukin 2</span></p>"
      },
      {
        "id": 43652,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It acts by binding to immunophilins</span></p>"
      },
      {
        "id": 43653,
        "text": "<p><span style=\"font-size:12.0pt;\">Hirsutism is more common than cyclosporine</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">All the following statements are true about tacrolimus except:</span></p>",
    "unique_key": "Q4902967",
    "question_audio": null,
    "question_video": null,
    "map_id": 36491,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D) Hirsutism is more common than cyclosporine</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The statement is<strong> incorrect. Hirsutism, or excessive hair growth</strong>, is a <strong>known side effect</strong> associated <strong>more frequently with cyclosporine,</strong> <strong>another immunosuppressant </strong>used in <strong>similar clinical settings</strong> as <strong>tacrolimus</strong>. <strong>Tacrolimus</strong> may cause<strong> hirsutism </strong>as well, but it is significantly<strong> less common</strong> compared to<strong> cyclosporine.</strong> Therefore, stating that <strong>hirsutism is more common with tacrolimus </strong>than with<strong> cyclosporine is false.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A. It is a macrolide lactone:</strong> <strong>True</strong>. <strong>Tacrolimus is a macrolide lactone</strong>; it is structurally similar to <strong>other macrolides</strong> like <strong>erythromycin and azithromycin</strong> but has a <strong>different function, primarily as an immunosuppressant.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B. It inhibits the gene transcription of interleukin 2:</strong> <strong>True</strong>.<strong> Tacrolimus</strong> i<strong>nhibits the activation of T-lymphocytes</strong> by<strong> inhibiting</strong> <strong>calcineurin</strong>, which in turn <strong>reduces the transcription of interleukin-2 (IL-2).</strong> IL-2 is critical for the<strong> growth and activation of T-cells</strong>, so its <strong>suppression</strong> is key to<strong> tacrolimus's ability </strong>to <strong>prevent organ rejection </strong>in<strong> transplant patients.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option C. It acts by binding to immunophilins:</strong> <strong>True</strong>. <strong>Tacrolimus</strong> binds specifically to the <strong>immunophilin</strong> known as <strong>FK506 binding</strong> <strong>protein (FKBP)</strong>, forming a <strong>complex</strong> that <strong>inhibits calcineurin,</strong> a necessary enzyme in the <strong>T-cell activation pathway.</strong> This action is crucial for <strong>its immunosuppressive effects.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">While <strong>tacrolimus</strong> shares some <strong>mechanisms of action</strong> with <strong>other immunosuppressants</strong> like <strong>cyclosporine,</strong> notably its <strong>suppression of T-cell activation</strong> via <strong>calcineurin inhibition</strong>, it <strong>does not </strong>cause <strong>hirsutism</strong> as commonly as cyclosporine does. This distinction is important in <strong>clinical practice </strong>when choosing an <strong>immunosuppressant</strong>, especially considering the <strong>side effect</strong> profiles that can affect <strong>patient compliance and quality of life.</strong></span></p>",
    "correct_choice_id": 43653,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10910,
    "choices": [
      {
        "id": 43606,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adamantinoma</span></span></span></p>"
      },
      {
        "id": 43607,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basal cell Ca</span></span></span></p>"
      },
      {
        "id": 43608,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colorectal Ca</span></span></span></p>"
      },
      {
        "id": 43609,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crohn&rsquo;s disease</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cetuximab is used for treatment of?</span></span></span></p>",
    "unique_key": "Q6649761",
    "question_audio": null,
    "question_video": null,
    "map_id": 36488,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Colorectal Ca</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cetuximab</strong> is a <strong>monoclonal antibody</strong> that targets the <strong>epidermal growth factor receptor (EGFR)</strong>, which is <strong>overexpressed</strong> in many <strong>types of cancers</strong>, including a <strong>significant proportion of colorectal cancers</strong>. By<strong> binding to EGFR, cetuximab inhibits</strong> the <strong>receptor&#39;s</strong> <strong>function</strong>, which is to <strong>trigger pathways</strong> that lead to<strong> cell growth and proliferation</strong>. This <strong>inhibition</strong> helps<strong> to control the growth </strong>of <strong>cancer cells, </strong>making <strong>cetuximab an effective treatment</strong> for<strong> colorectal cancer, </strong>particularly in <strong>tumors</strong> that express <strong>high levels of EGFR.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adamantinoma:</span></strong><span style=\"font-size:12.0pt\"> This is a<strong> rare</strong> type of<strong> tumor</strong> that typically<strong> arises in the bones,</strong> specifically the <strong>tibia and the jawbone.</strong> <strong>Cetuximab</strong> is<strong> not</strong> indicated for the<strong> treatment of adamantinoma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Basal cell Ca (Carcinoma):</span></strong><span style=\"font-size:12.0pt\"> Basal cell carcinoma is primarily<strong> treated</strong> with <strong>surgical methods, topical treatments, </strong>or <strong>radiation</strong> <strong>therapy.</strong> <strong>Cetuximab</strong> is<strong> not</strong> used for <strong>basal cell carcinoma</strong> as it generally <strong>does not </strong>express<strong> EGFR </strong>to a significant extent.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Crohn&rsquo;s disease:</span></strong><span style=\"font-size:12.0pt\"> This is an <strong>inflammatory bowel disease</strong>; treatment typically involves <strong>immunosuppressive </strong>and <strong>anti-inflammatory agents</strong> such as <strong>TNF&alpha; inhibitors (e.g., infliximab). Cetuximab</strong> has <strong>no</strong> role in the <strong>treatment of Crohn&#39;s disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">MONOCLONAL ANTIBODIES</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-130406.png\" style=\"height:713px; width:1000px\" /></span></strong></span></span></p>",
    "correct_choice_id": 43608,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 10911,
    "choices": [
      {
        "id": 43610,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avelumab</span></span></span></p>"
      },
      {
        "id": 43611,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atezolizumab</span></span></span></p>"
      },
      {
        "id": 43612,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cetuximab</span></span></span></p>"
      },
      {
        "id": 43613,
        "text": "<p style=\"margin-right:-1px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Durvalumab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the following are PD-L1 inhibitors except?</span></span></span></p>",
    "unique_key": "Q7237449",
    "question_audio": null,
    "question_video": null,
    "map_id": 36489,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cetuximab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cetuximab </strong>is a<strong> monoclonal antibody </strong>that specifically targets the <strong>epidermal growth factor receptor (EGFR) </strong>on the <strong>surface of cancer</strong> <strong>cells.</strong> It functions by<strong> inhibiting EGFR</strong> and its<strong> associated signaling pathways</strong>, which are often <strong>upregulated in various types of cancers,</strong> particularly<strong> colorectal and head and neck cancers</strong>. This mechanism is <strong>distinct from the mode of action of PD-L1 inhibitors</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/402.jpg\" style=\"height:333px; width:500px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Avelumab:</span></strong><span style=\"font-size:12.0pt\"> Avelumab is a <strong>PD-L1 inhibitor </strong>that <strong>blocks the interaction between PD-L1 on tumor cells </strong>and<strong> PD-1 on T cells.</strong> By doing so, it<strong> prevents </strong>the<strong> tumor</strong> from evading the<strong> immune response, enabling the immune system </strong>to attack the <strong>cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Atezolizumab:</span></strong><span style=\"font-size:12.0pt\"> Similar to<strong> Avelumab,</strong> Atezolizumab is a<strong> monoclonal antibody </strong>that binds to <strong>PD-L1,</strong> <strong>inhibiting </strong>its <strong>interaction</strong> with<strong> PD-1</strong>. This <strong>blockade </strong>enhances the<strong> body&#39;s immune response against tumor cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Durvalumab:</span></strong><span style=\"font-size:12.0pt\"> Durvalumab also<strong> targets PD-L1</strong>, <strong>preventing</strong> it from <strong>binding to PD-1.</strong> It is part of the<strong> group of immune</strong> <strong>checkpoint inhibitors</strong> that help to<strong> activate the immune system against cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While <strong>Avelumab, Atezolizumab, and Durvalumab </strong>are <strong>all PD-L1 inhibitors</strong> enhancing the<strong> immune system&#39;s ability to fight cancer,</strong> <strong>Cetuximab</strong> works through a<strong> different mechanism </strong>by <strong>targeting EGFR on cancer cells</strong>.&nbsp;</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Immune Check Point inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-131641.png\" style=\"height:247px; width:1000px\" /></p>",
    "correct_choice_id": 43612,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10900,
    "choices": [
      {
        "id": 43566,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a chimeric monoclonal antibody against CD-20</span></span></span></p>"
      },
      {
        "id": 43567,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It has dose dependent kinetics</span></span></span></p>"
      },
      {
        "id": 43568,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is used for treatment of non- Hodgkin lymphoma</span></span></span></p>"
      },
      {
        "id": 43569,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Its most common adverse effect is infusion related reactions</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements about rituximab is false? </span></span></span></p>",
    "unique_key": "Q3931391",
    "question_audio": null,
    "question_video": null,
    "map_id": 36484,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) It has dose dependent kinetics.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab</strong> is <strong>chimeric monoclonal antibody </strong>against <strong>CD-20 B-cells. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab</strong> follows<strong> first order kinetics.</strong> Its<strong> clearance</strong> remains<strong> constant irrespective of plasma concentration. Dose-dependent kinetics</strong> means <strong>zero-order kinetics</strong> i.e. <strong>clearance and t1/2 change</strong> with <strong>dose (plasma concentration).</strong> Drugs following<strong> zero-order kinetics</strong> are <strong>warfarin, alcohol, high dose aspirin, tolbutamide, theophylline and phenytoin. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Infusion-related </strong>reactions are seen in approximately<strong> 50% </strong>of patients receiving<strong> first infusion</strong>. The <strong>incidence decreases</strong> with <strong>subsequent infusions.</strong> Starting with <strong>low doses </strong>and <strong>pre-treatment</strong> with <strong>steroids or anti-histaminic </strong>are the <strong>methods</strong> to <strong>reduce infusion related reactions. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab</strong> may cause <strong>reactivation of hepatitis B;</strong> therefore, patients should be <strong>screened for hepatitis B</strong> before <strong>initiation</strong> of therapy. It rarely<strong> causes reactivation of JC virus </strong>leading to <strong>progressive multifocal leukoencephalopathy. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab </strong>can be<strong> used for treatment</strong> of </span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-Hodgkin lymphoma </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mantle cell lymphoma </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic lymphocytic leukemia </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Auto-immune hemolytic anemia </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diffuse large B cell lymphoma. </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rheumatoid arthritis </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It is a chimeric monoclonal antibody against CD-20:</span></strong><span style=\"font-size:12.0pt\"> This statement is <strong>true</strong> and accurately describes the <strong>biological target </strong>of<strong> rituximab,</strong> essential for<strong> its efficacy in treating diseases</strong> like<strong> lymphomas </strong>where<strong> CD-20 positive B-cells are pathologically active.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. It is used for treatment of non-Hodgkin lymphoma:</span></strong><span style=\"font-size:12.0pt\"> <strong>True. Rituximab </strong>is extensively<strong> used in</strong> the treatment of <strong>non-Hodgkin</strong> <strong>lymphoma</strong> among other<strong> lymphoid malignancies, </strong>leveraging its ability to target<strong> CD-20 </strong>for<strong> therapeutic effect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Its most common adverse effect is infusion related reactions:</span></strong><span style=\"font-size:12.0pt\"> Also <strong>true</strong>.<strong> Infusion-related reactions</strong> occur in about<strong> half of</strong> <strong>all patients </strong>during the <strong>first infusion of rituximab,</strong> though the <strong>risk decreases</strong> with <strong>subsequent treatments.</strong> <strong>Pre-medicating </strong>with <strong>steroids or antihistamines </strong>can<strong> mitigate</strong> these reactions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Rituximab,</strong> a <strong>chimeric monoclonal antibody</strong> targeting CD-20 B-cells, is <strong>primarily used </strong>to treat various<strong> hematological malignancies</strong> and some <strong>autoimmune conditions</strong>. Its <strong>pharmacokinetics does not</strong> follow<strong> dose-dependent kinetics </strong>but instead<strong> exhibits first-order</strong> <strong>kinetics,</strong> meaning its<strong> clearance remains constant </strong>across<strong> different plasma concentrations.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In<strong> contrast,</strong> <strong>dose-dependent kinetics (zero-order kinetics) </strong>describes a scenario where the<strong> drug&rsquo;s clearance rate and half-life </strong>change with<strong> varying doses</strong>, which is<strong> not</strong> the case with <strong>rituximab</strong>. This <strong>differentiates rituximab </strong>from drugs like <strong>warfarin and phenytoin</strong>, which follow<strong> zero-order kinetics</strong> at <strong>therapeutic or higher doses.</strong></span></span></span></p>",
    "correct_choice_id": 43567,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10902,
    "choices": [
      {
        "id": 43574,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is an antibody produced entirely from mice containing no human component</span></span></span></p>"
      },
      {
        "id": 43575,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a monoclonal antibody produced by injecting the HER2 antigen</span></span></span></p>"
      },
      {
        "id": 43576,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a polyclonal antibody</span></span></span></p>"
      },
      {
        "id": 43577,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is a monoclonal antibody containing only human components</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old female presents with breast carcinoma, and she was prescribed Herceptin (trastuzumab). Which of the following statements regarding this drug is true?</span></span></span></p>",
    "unique_key": "Q9739289",
    "question_audio": null,
    "question_video": null,
    "map_id": 36485,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) It is a monoclonal antibody produced by injecting the HER2 antigen</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Herceptin (trastuzumab)</strong> is a <strong>monoclonal antibody</strong> that specifically targets the<strong> human epidermal growth factor receptor</strong> <strong>2 (HER2) protein</strong>, which is <strong>overexpressed </strong>in approximately <strong>25% of breast cancers</strong>. It is produced by <strong>injecting</strong><strong> </strong>the <strong>HER2 antigen</strong> into<strong> mice </strong>and then<strong> harvesting the resulting monoclonal antibodies.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> <strong>It is an antibody produced entirely from mice containing no human component:</strong> This statement is <strong>incorrect.</strong> <strong>Trastuzumab</strong> is<strong> not</strong> a<strong> fully murine </strong>(<strong>mouse-derived</strong>) <strong>antibody.</strong> It is, in fact, a<strong> humanized monoclonal antibody, </strong>which means it is<strong> predominantly of</strong> <strong>human origin</strong>, but with <strong>mouse-derived antigen-binding regions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option C. It is a polyclonal antibody:</strong> This statement is<strong> incorrect. Trastuzumab</strong> is a <strong>monoclonal antibody,</strong> meaning it is made by <strong>identical immune cells</strong> that are all<strong> clones</strong> of a <strong>unique parent cell</strong>, and it <strong>targets a specific epitope</strong> on the <strong>HER2 receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>It is a monoclonal antibody containing only human components: </strong>This is <strong>not accurate</strong>. <strong>Trastuzumab </strong>is <strong>humanized,</strong> meaning it <strong>combines both human and mouse antibody components.</strong> The <strong>majority</strong> of the<strong> antibody is human,</strong> with <strong>mouse</strong> <strong>components</strong> in the<strong> antigen-binding region.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trastuzumab (Herceptin)</strong> is a<strong> humanized monoclonal antibody </strong>used in the treatment of <strong>HER2-positive breast cancer.</strong> It is crucial to understand that it<strong> targets the HER2 receptor,</strong> which is <strong>overexpressed </strong>in certain <strong>aggressive forms of breast cancer</strong>, helping to<strong> inhibit</strong> the <strong>growth and&nbsp;</strong></span></span><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">spread of cancer cells. </span></span></span></strong></p>",
    "correct_choice_id": 43575,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 10914,
    "choices": [
      {
        "id": 43622,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxorubicin</span></span></span></p>"
      },
      {
        "id": 43623,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carboplatin</span></span></span></p>"
      },
      {
        "id": 43624,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate</span></span></span></p>"
      },
      {
        "id": 43625,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cetuximab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with head and neck cancer was given radiotherapy. After 6 months of radiotherapy, chemotherapy was started but patient presented with the clinical picture as shown after start of chemotherapy. What is the likely drug responsible for this?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/405.jpg\" style=\"height:271px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q3399549",
    "question_audio": null,
    "question_video": null,
    "map_id": 36481,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Doxorubicin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical picture shows <strong>&lsquo;radiation recall syndrome&rsquo;</strong>. The <strong>causative agent is Doxorubicin</strong>.</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Radiation recall syndrome (RRS)</strong> is characterized by an <strong>acute inflammatory reaction</strong> in previously<strong> irradiated</strong> <strong>areas of the body,</strong> usually <strong>occurring within days to weeks</strong> of <strong>administration of anticancer drugs.</strong> The hallmark of <strong>RRS is erythema</strong>, which can <strong>progress to blistering, ulceration, and desquamation.</strong></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> exact </strong>cause of<strong> RRS</strong> is<strong> not well understood,</strong> but it is thought to be related to an <strong>interaction between</strong> the <strong>chemotherapy drugs </strong>and the <strong>radiation therapy.</strong> <strong>Radiation therapy can</strong> cause<strong> damage to the DNA of cells</strong> in the<strong> target area,</strong> and this <strong>damage can persist </strong>for some time. <strong>If chemotherapy</strong> is<strong> administered </strong>after<strong> radiation</strong> <strong>therapy,</strong> it may <strong>interact</strong> with this <strong>residual radiation damage, triggering an inflammatory response</strong> in the <strong>previously irradiated tissue</strong> and causing the symptoms of <strong>RRS.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carboplatin:</span></strong><span style=\"font-size:12.0pt\"> While <strong>Carboplatin</strong> can have a <strong>variety of side effects,</strong> it is <strong>less </strong>commonly associated with <strong>radiation recall</strong> <strong>syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Methotrexate:</span></strong><span style=\"font-size:12.0pt\"><strong> Methotrexate</strong> can cause<strong> mucositis and skin reactions </strong>but is<strong> not </strong>typically associated with<strong> radiation recall.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cetuximab:</span></strong><span style=\"font-size:12.0pt\"> <strong>Cetuximab</strong>, a <strong>monoclonal antibody targeting EGFR,</strong> is associated with <strong>skin reactions;</strong> however, it is <strong>not</strong> <strong>typically</strong> cited as a<strong> cause of radiation recall syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>most common drugs</strong> associated with<strong> RRS are anthracyclines</strong> (such a<strong>s doxorubicin</strong>), <strong>taxanes</strong> (such as <strong>paclitaxel</strong>), and <strong>gemcitabine. </strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 43622,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 10923,
    "choices": [
      {
        "id": 43658,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pembrolizumab </span></span></span></p>"
      },
      {
        "id": 43659,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Trastuzumab</span></span></span></p>"
      },
      {
        "id": 43660,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab</span></span></span></p>"
      },
      {
        "id": 43661,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ocrelizumab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal antibody used in Head and Neck cancer is? </span></span></span></p>",
    "unique_key": "Q5847493",
    "question_audio": null,
    "question_video": null,
    "map_id": 36482,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Pembrolizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pembrolizumab</strong>: Pembrolizumab is a <strong>monoclonal antibody</strong> that targets the <strong>programmed death 1 (PD-1) receptor on T</strong> <strong>cells</strong>, which helps to <strong>stimulate</strong> an<strong> immune response against cancer cells.</strong> This therapy has been approved by the <strong>FDA to</strong> <strong>treat head and neck cancer, </strong>as well as other types of cancer such as <strong>melanoma, non-small cell lung cancer, and Hodgkin lymphoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> <strong>Trastuzumab</strong>: Trastuzumab is a<strong> monoclonal antibody</strong> that is <strong>used</strong> to treat <strong>HER2-positive breast cancer, </strong>which is a type of <strong>breast cancer</strong> that has <strong>high levels of the protein HER2</strong> on the<strong> surface</strong> of the <strong>cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> <strong>Rituximab</strong>: Rituximab is a<strong> monoclonal antibody</strong> that is used to treat non-Hodgkin&#39;s lymphoma, <strong>chronic lymphocytic</strong> <strong>leukemia, and rheumatoid arthritis</strong>. It works by <strong>targeting a protein </strong>called <strong>CD20 </strong>on the <strong>surface of B cells</strong>, which are a type of <strong>immune cell </strong>that can become<strong> cancerous </strong>in certain conditions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Ocrelizumab</strong>: Ocrelizumab is a <strong>monoclonal antibody</strong> that is<strong> used to treat multiple sclerosis, a chronic autoimmune disease</strong> that affects the<strong> central nervous system</strong>. It<strong> targets a protein</strong> called<strong> CD20 on B cells,</strong> which are thought to play a role in the <strong>development of the disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pembrolizumab </strong>is utilized in the treatment of<strong> head and neck cancer </strong>due to its ability to <strong>enhance </strong>the <strong>immune response </strong>against <strong>cancer cells by inhibiting the PD-1 pathway</strong>. This action <strong>helps to counteract the immune evasion tactics </strong>employed by many <strong>cancers,</strong> <strong>highlighting </strong>the importance of<strong> immune checkpoint inhibitors</strong> in <strong>modern oncology.</strong></span></span></span></p>",
    "correct_choice_id": 43658,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10925,
    "choices": [
      {
        "id": 43666,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ustekinumab</span></span></span></p>"
      },
      {
        "id": 43667,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brodalumab</span></span></span></p>"
      },
      {
        "id": 43668,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Secukinumab</span></span></span></p>"
      },
      {
        "id": 43669,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarilumab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All are monoclonal antibodies approved for use in psoriasis, Except:</span></span></span></p>",
    "unique_key": "Q9284368",
    "question_audio": null,
    "question_video": null,
    "map_id": 36483,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Sarilumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>monoclonal antibodies</strong> approved for use in <strong>psoriasis</strong> are <strong>Ustekinumab, Brodalumab, and Secukinumab.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Sarilumab</strong> is a<strong> monoclonal antibody</strong> that targets the<strong> interleukin-6 (IL-6) receptor</strong> and is approved for the treatment of <strong>rheumatoid arthritis,</strong> but it is<strong> not </strong>approved for use in<strong> psoriasis.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ustekinumab:</span></strong><span style=\"font-size:12.0pt\"> This <strong>monoclonal antibody </strong>targets both <strong>interleukin-12 (IL-12) and interleukin-23 (IL-23).</strong> It is approved for the treatment of<strong> psoriasis, psoriatic arthritis, and Crohn&#39;s disease.</strong> It works by<strong> modulating the immune response </strong>that contributes to the<strong> inflammation</strong> characteristic of these conditions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Brodalumab:</span></strong><span style=\"font-size:12.0pt\"> <strong>Targets</strong> the<strong> interleukin-17 (IL-17) receptor,</strong> approved for the treatment of<strong> psoriasis.</strong> By <strong>blocking IL-17,</strong> <strong>Brodalumab</strong> helps <strong>reduce inflammation </strong>and the<strong> rapid skin cell </strong>turnover associated with <strong>psoriasis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Secukinumab:</span></strong><span style=\"font-size:12.0pt\"> This <strong>antibody targets interleukin-17A (IL-17A) </strong>and is approved for <strong>psoriasis, psoriatic arthritis,</strong> and <strong>ankylosing spondylitis</strong>. It works similarly to<strong> Brodalumab </strong>by targeting a key<strong> cytokine</strong> involved in<strong> inflammatory processes</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While<strong> Ustekinumab, Brodalumab, and Secukinumab</strong> are <strong>approved </strong>and <strong>effective </strong>treatments for<strong> psoriasis</strong> through their<strong> targeting </strong>of <strong>specific interleukins</strong> involved in <strong>inflammatory pathways,</strong> <strong>Sarilumab,</strong> though a <strong>monoclonal antibody</strong>, is <strong>not</strong> used for <strong>psoriasis</strong> as it <strong>targets IL-6</strong>, <strong>relevant primarily</strong> in the context of<strong> rheumatoid arthritis. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Monoclonal antibodies for psoriasis:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-150951.png\" style=\"height:541px; width:700px\" /></span></strong></span></span></p>",
    "correct_choice_id": 43669,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10938,
    "choices": [
      {
        "id": 43718,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Alemtuzumab</span></span></span></p>"
      },
      {
        "id": 43719,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ocrelizumab</span></span></span></p>"
      },
      {
        "id": 43720,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Natalizumab</span></span></span></p>"
      },
      {
        "id": 43721,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pertuzumab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is a US-FDA approved anti-CD 20 monoclonal antibody for primary progressive multiple sclerosis? </span></span></span></p>",
    "unique_key": "Q5768620",
    "question_audio": null,
    "question_video": null,
    "map_id": 36487,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Ocrelizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ocrelizumab</strong> is an <strong>anti-CD20 monoclonal antibody </strong>approved by the <strong>US-FDA</strong> for the<strong> treatment of primary progressive</strong> <strong>multiple sclerosis (PPMS),</strong> as well as for<strong> relapsing forms of multiple sclerosis (RMS)</strong>. Its <strong>mechanism of action </strong>involves binding to<strong> CD20-positive B cells</strong>, which play a significant role in the <strong>inflammatory process of multiple sclerosis.</strong> By <strong>depleting these B cells, ocrelizumab reduces the inflammatory activity</strong> and can <strong>slow the progression of the disease.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Alemtuzumab:</span></strong><span style=\"font-size:12.0pt\"> Alemtuzumab<strong> targets CD52</strong>, a<strong> protein </strong>expressed on the <strong>surface of T and B lymphocytes</strong>, and is <strong>used in </strong>the treatment of <strong>relapsing-remitting multiple sclerosis,</strong> but not for PPMS.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Natalizumab:</span></strong><span style=\"font-size:12.0pt\"> Natalizumab <strong>targets integrin alpha-4</strong>, involved in the<strong> migration of leukocytes across the blood-brain barrier.</strong> It is <strong>used</strong> for <strong>relapsing forms of multiple sclerosis</strong> and not indicated for PPMS.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pertuzumab:</span></strong><span style=\"font-size:12.0pt\"> Pertuzumab is a<strong> monoclonal antibody </strong>that <strong>targets the HER2 receptor,</strong> which is <strong>overexpressed in HER2-positive breast cancer.</strong> It is <strong>not</strong> used in the<strong> treatment of multiple sclerosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Ocrelizumab </strong>is the<strong> first and only US-FDA </strong>approved therapy specifically indicated for <strong>primary progressive multiple sclerosis.</strong></span></span></span></p>",
    "correct_choice_id": 43719,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 10936,
    "choices": [
      {
        "id": 43710,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hodgkin&rsquo;s lymphoma</span></span></span></p>"
      },
      {
        "id": 43711,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Medulloblastoma</span></span></span></p>"
      },
      {
        "id": 43712,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinoblastoma</span></span></span></p>"
      },
      {
        "id": 43713,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Endometrial carcinoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nivolumab is used in the treatment of?</span></span></span></p>",
    "unique_key": "Q8755280",
    "question_audio": null,
    "question_video": null,
    "map_id": 36486,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Hodgkin&rsquo;s lymphoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Nivolumab</span></strong><span style=\"font-size:12.0pt\"> is a<strong> checkpoint inhibitor</strong> that targets the <strong>PD-1 (programmed cell death protein 1) on T cells</strong>. It is<strong> used</strong> in the treatment of <strong>various cancers, including Hodgkin&rsquo;s lymphoma.</strong> <strong>Nivolumab </strong>works by <strong>blocking PD-1, enhancing the immune system&#39;s response</strong> <strong>against cancer cells. </strong>It has been particularly <strong>effective</strong> in treating <strong>classical Hodgkin&#39;s lymphoma,</strong> especially in<strong> cases </strong>that are <strong>refractory</strong> to<strong> other treatments.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Medulloblastoma:</span></strong><span style=\"font-size:12.0pt\"><strong> Not</strong> a primary indication for <strong>nivolumab.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Retinoblastoma:</span></strong><span style=\"font-size:12.0pt\"> <strong>Not</strong> treated with <strong>nivolumab.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Endometrial carcinoma:</span></strong><span style=\"font-size:12.0pt\"> <strong>Pembrolizumab</strong> is more commonly associated with <strong>endometrial carcinoma, not nivolumab.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Important<strong> indications</strong> of <strong>Immune Check Point Inhibitors</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/416.jpg\" style=\"height:742px; width:1000px\" /></span></span></span></p>",
    "correct_choice_id": 43710,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Anti-Cancer Drugs & Immunosuppressants';
        let hierarchy = ["Cerebellum", "qBank", "Pharmacology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }
            
            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>